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1.0 Abstract 
 
Common bile duct stones (CBDS) are estimated to be present in 10-20% of 
individuals with symptomatic gallstones. They can result in a number of health problems, 
including pain, jaundice, infection and acute pancreatitis. A variety of imaging modalities can 
be employed to identify the condition, whilst management of confirmed cases of CBDS may 
involve endoscopic retrograde cholangiopancreatography (ERCP), surgery and radiological 
methods of stone extraction. 
 
Clinicians are therefore confronted with a number of potentially valid options to 
diagnose and treat individuals with suspected CBDS. The British Society of Gastroenterology 
(BSG) first published a guideline on the management of CBDS in 2008. Since then a number 
of developments in management have occurred along with further systematic reviews of the 
available evidence. The following recommendations reflect these changes and provide 
updated guidance to health care professionals who are involved in the care of adult patients 
with suspected or proven CBDS. It is not a protocol and the recommendations contained 
within should not replace individual clinical judgment. 
 
 
2.0 Summary of recommendations 
 
Where recommendations from the 2008 guidelines,[1] are obsolete they are 
omitted. Where recommendations are prefaced by ‘(2008)’ there has been no new evidence 
found since the last guideline and no change in the recommendation; ‘(2008 amended 
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2016)’ indicates that whilst no new  evidence has been found since the last guideline there 
has been a  change  in wording that effects the meaning of the recommendation; ‘(2016)’ 
indicates that new evidence has been found and no change in the recommendation is 
necessary; ‘(New 2016)’ indicates that new evidence has resulted in a new or amended 
recommendation. 
 
2.1 General principles in management of CBDS 
 
2.1.1 (New 2016). It is recommended that patients diagnosed with CBDS are offered stone 
extraction if possible. Evidence of benefit is greatest for symptomatic patients. (Low quality 
evidence; strong recommendation). 
 
2.2 Identifying individuals with CBDS 
 
2.2.1 (New 2016). Trans-abdominal ultrasound scanning (USS) and Liver function tests (LFTs) 
are recommended for patients with suspected CBDS. Normal results do not preclude further 
investigation if clinical suspicion remains high. (Low quality evidence; strong 
recommendation). 
 
2.2.2 (New 2016). Magnetic resonance cholangiopancreatography (MRCP) and endoscopic 
ultrasound (EUS) are both recommended as highly accurate tests for identifying CBDS among 
patients with an intermediate probability of disease. MRCP predominates in this role, with 
choice between the two modalities determined by individual suitability, availability of the 
relevant test, local expertise and patient acceptability. (Moderate quality evidence; strong 
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recommendation). 
 
2.2.3 (New 2016). It is suggested that patients with suspected CBDS who have not been 
previously investigated should undergo USS and LFTs. For patients with an intermediate 
probability of stones MRCP or EUS is recommended as a next step, unless the patient is 
proceeding directly to cholecystectomy supplemented by intra-operative cholangiography 
(IOC) or laparoscopic ultrasound (LUS). ERCP should be reserved for patients in whom 
preceding assessment indicates a need for endoscopic therapy. (Low quality evidence; weak 
recommendation). 
 
2.3 Endoscopic management of CBDS 
 
2.3.1 (New 2016). It is suggested that the BSG national standards framework for ERCP is 
implemented by service providers. (Very low quality evidence; weak recommendation). 
 
2.3.2 (New 2016). For selected patients, tolerability and likelihood of therapeutic success is 
higher if ERCP is performed with propofol sedation or general anaesthesia. It is 
recommended that hospitals looking after patients with CBDS should have ready and 
prompt access to anaesthesia supported ERCP. This can be an onsite service or provided by 
another ERCP unit as part of a clinical network. (Low quality evidence; strong 
recommendation). 
 
2.3.3 (2008). It is suggested that patients should be managed in accordance with the BSG 
guidelines on antibiotic prophylaxis during endoscopy. (Very low quality evidence; weak 
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recommendation). 
 
2.3.4 (New 2016). To reduce the risk of post ERCP pancreatitis (PEP) it is recommended that 
diclofenac or indomethacin (at a dose of 100 mg) should be administered rectally at the time 
of ERCP to all patients who do not have a contraindication to non-steroidal anti-
inflammatory drugs (NSAIDs). (Moderate quality evidence; strong recommendation). 
 
2.3.5 (New 2016). In patients with a high risk of PEP arising from repeated pancreatic duct 
cannulation, insertion of a pancreatic stent is suggested in addition to administration of 
rectal NSAID. (Moderate quality evidence; weak recommendation). 
 
2.3.6 (2008 amended 2016).  It is recommended that patients undergoing biliary 
sphincterotomy for ductal stones have a full blood count (FBC) and international normalised 
ratio or prothrombin time (INR/PT) performed prior to their ERCP. If deranged clotting or 
thrombocytopenia is identified, subsequent management should conform to locally agreed 
guidelines. (Low quality evidence; strong recommendation). 
 
2.3.7 (New 2016). It is recommended that ERCP patients taking warfarin, anti-platelet 
treatment or a direct oral anticoagulant (DOAC) should be managed in accordance with the 
combined BSG and European Society of Gastrointestinal Endoscopy (ESGE) guidelines for 
patients undergoing endoscopy. (Low quality evidence; strong recommendation). 
 
2.3.8 (2008, amended 2016). Competency in access papillotomy is suggested for all 
endoscopists who perform ERCP. Training and subsequent mentorship should facilitate this. 
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(Very low quality evidence; weak recommendation). 
 
2.3.9 (New 2016). As an adjunct to biliary sphincterotomy endoscopic papillary balloon 
dilation (EPBD) is recommended as a technique to facilitate removal of large CBDS. (Low 
quality evidence; strong recommendation). 
 
2.3.10 (New 2016). EPBD without prior biliary sphincterotomy is associated with an 
increased risk of PEP but may be considered as an alternative to biliary sphincterotomy in 
selected patients, such as those with an uncorrected coagulopathy or difficult biliary access 
due to altered anatomy. If EPBD is performed without prior biliary sphincterotomy use of an 
8mm diameter balloon is recommended. (Moderate quality evidence; strong 
recommendation). 
 
 
2.3.11 (New 2016). It is recommended that cholangioscopy-guided electrohydraulic 
lithotripsy (EHL) or laser lithotripsy (LL) be considered when other endoscopic treatment 
options fail to achieve duct clearance. (Low quality evidence; strong recommendation). 
 
2.4 Surgical management of CBDS 
 
2.4.1 (New 2016). IOC or LUS can be used to detect CBDS in patients who are suitable for 
surgical exploration or post-operative ERCP. Though not considered mandatory for all 
patients undergoing cholecystectomy, IOC or LUS is suggested for those patients who have 
an intermediate to high pre-test probability of CBDS and who have not had the diagnosis 
confirmed pre-operatively by USS, MRCP or EUS. (Low quality evidence; weak 
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recommendation). 
 
2.4.2 (2016). It is recommended that, in patients undergoing laparoscopic cholecystectomy, 
trans-cystic or trans-ductal laparoscopic bile duct exploration (LBDE) is an appropriate 
technique for CBDS removal.  There is no evidence of a difference in efficacy, mortality or 
morbidity when LBDE is compared to peri-operative ERCP, though LBDE is associated with a 
shorter hospital stay. It is recommended that the two approaches are considered equally 
valid treatment options (High quality evidence; strong recommendation). 
 
2.4.3 (New 2016). It is suggested that training of surgeons in LBDE is to be encouraged in 
order to decrease the number of interventions required to manage CBDS. (Low quality 
evidence; weak recommendation). 
 
 
2.5 Management of “difficult” ductal stones 
 
2.5.1 (New 2016). Laparoscopic duct exploration and ERCP (supplemented by EPBD with 
prior sphincterotomy, mechanical lithotripsy or cholangioscopy where necessary) are highly 
successful in removing CBDS. It is recommended that percutaneous radiological stone 
extraction and open duct exploration should be reserved for the small number of patients in 
whom these techniques fail or are not possible. (Low quality evidence; strong 
recommendation) 
 
2.5.2 (New 2016). When endoscopic cannulation of the bile duct is not possible with 
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standard techniques including access papillotomy, it is recommended that percutaneous or 
EUS guided procedures can be considered as a means of facilitating subsequent ERCP. (Low 
quality evidence; strong recommendation). 
 
2.5.3 (2016). It is important that endoscopists ensure adequate biliary drainage is achieved 
in patients with CBDS that have not been extracted. The short-term use of a biliary stent 
followed by further endoscopy or surgery is recommended.  (Moderate quality evidence; 
strong recommendation) 
 
2.5.4 (2016). The use of a biliary stent as sole treatment for CBDS should be restricted to a 
selected group of patients with limited life expectancy and/or prohibitive surgical risk. 
(Moderate quality evidence; strong recommendation). 
 
2.6 Management of CBDS in specific clinical setting 
 
2.6.1 (New 2016). Cholecystectomy is recommended for all patients with CBDS and 
gallbladder stones, unless there are specific reasons for considering surgery inappropriate. 
(High quality evidence; strong recommendation). 
Where operative risk is deemed prohibitive biliary sphincterotomy and endoscopic duct 
clearance alone is suggested as an acceptable alternative. (Very low quality evidence; weak 
recommendation). 
 
2.6.2 (2008). Biliary sphincterotomy and endoscopic stone extraction is recommended as the 
primary form of treatment for patients with CBDS post cholecystectomy. (Low quality 
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evidence; strong recommendation). 
 
2.6.3 (New 2016). Patients with acute cholangitis who fail to respond to antibiotic therapy or 
who have signs of septic shock require urgent biliary decompression. Endoscopic CBDS 
extraction and/or biliary stenting are recommended in this setting. If ERCP is not possible 
percutaneous radiological drainage can be considered as an alternative. (Moderate quality 
evidence; strong recommendation). 
 
2.6.4 (New 2016). Patients with pancreatitis of suspected or proven biliary origin who have 
associated cholangitis or persistent biliary obstruction are recommended to undergo biliary 
sphincterotomy and endoscopic stone extraction within 72 hours of presentation. (High 
quality evidence; strong recommendation). 
 
2.6.5 (New 2016). It is recommended that following gallstone pancreatitis early laparoscopic 
cholecystectomy should be offered to all patients on whom it is safe to operate, as the most 
effective means to prevent recurrent episodes. (Moderate quality evidence, strong 
recommendation). 
 
2.6.6 (New 2016). In cases of mild acute gallstone pancreatitis it is suggested that 
cholecystectomy should be performed within 2 weeks of presentation and preferably during 
same admission. (Moderate quality evidence; weak recommendation). 
 
2.6.7 (New 2016).  It is recommended that patients with gallstone pancreatitis who do not 
require ERCP within 72h of presentation should be considered for elective ERCP and 
REVISED MARKED COPY, NOV 2016.  13 
endoscopic sphincterotomy if there is evidence of retained CBDS on imaging or the patient is 
unsuitable for definitive treatment in the form of cholecystectomy. (Moderate quality 
evidence; strong recommendation). 
 
2.6.8 (New 2016). ERCP for CBDS extraction can be successfully performed in patients with 
Billroth II anatomy. Where ERCP with a duodenoscope is difficult use of a forward viewing 
scope is recommended. (Moderate quality evidence; weak recommendation). In cases 
where biliary sphincterotomy cannot be safely completed a limited sphincterotomy 
supplemented by EPBD is suggested as an alternative. (Low quality evidence; weak 
recommendation). 
 
2.6.9 (New 2016). Patients with Roux-en-Y gastric bypass (RYGB) and CBDS should be 
referred to centres that are able to offer the advanced endsoscopic and surgical treatment 
options that are necessary for stone extraction. (Low quality evidence; weak 
recommendation). 
 
3.0 Members of guideline development group and acknowledgements 
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4.0 Development process for current guideline 
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The updated guideline was commissioned by the BSG in 2014. The purpose of the 
updated guideline was to provide guidance to health care professionals who are involved in 
the care of adult patients with suspected or proven CBDS. The chair convened a GDG, 
consisting of clinicians and patients with experience in this area.  Members of the GDG were 
selected to ensure relevant professional bodies and specialities were represented. Authors 
were required to declare any interests. The AGREE II instrument, [2] was used as a 
framework to assist in guideline development. Key questions were derived from the content 
of the previous guideline and can be summarised as: 
1. When should investigation and treatment for CBDS be considered? (Section 5.0) 
2. What is the best way of identifying patients with CBDS? (Section 6.0) 
3.  When undertaking ERCP for CBDS what can be done to improve success rates and 
minimize risk? (Section 7.0) 
4. What is the role of surgery in managing CBDS? (Section 8.0) 
5. In patients with CBDS that are difficult to treat what are the management options? 
(Section 9.0) 
6. How should CBDS be managed in the most commonly encountered clinical settings? 
(Section 10.0) 
A literature search was performed using Pubmed and Medline. The search terms 
employed were: common bile duct stones, gallstones, choledocholithiasis, laparoscopic 
cholecystectomy, ERCP, sphincteroplasty, and cholangioscopy. The search was restricted to 
English language articles published 6 months before the last BSG guideline or later (i.e. June 
2007 onwards). 
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Articles were selected by title and their relevance confirmed by review of the 
corresponding abstract. Systematic reviews and full length reports of prospective design 
were sought. Retrospective analyses and case reports were also retrieved if the topic had 
not been addressed by prospective study. Guidelines published by national and 
international bodies were automatically included for review. Data published in abstract 
form only were considered if full length papers addressing the same issue were lacking.  
 
The GDG corresponded with one another to identify the principal clinical 
developments since publication of the 2008 guideline. The topics that would need to be 
addressed in order to answer the key questions were agreed at this point and each section 
of the guideline was assigned a lead author. Upon completion of the literature search 
section leads drafted preliminary recommendations linked to a referenced narrative. As part 
of this they were asked to search the reference lists of retrieved papers for missing articles 
and were also free to suggest additional references for consideration. The GDG met at 
University College Hospital London on December 13th 2014. The output from each section 
lead was reviewed and each recommendation contained within the 2008 guidelines was 
considered and judged as being still valid, in need of revision, obsolete or no longer valid. A 
new set of recommendations were generated at this meeting. Evidence was graded for each 
recommendation by discussion and consensus among the GDG members, based on the 
group’s confidence in the effect of an intervention and whether further research was likely 
to alter confidence in the estimate (table 1). The GDG took account of the principles of the 
GRADE working group, [3] and considered risk of bias in the included studies, inconsistency, 
indirectness, imprecision, and publication bias.  However, given the large number of 
interventions examined the group did not attempt to produce outcome tables with pooled 
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estimates of effect.  Recommendations were graded as either strong or weak (table 2). 
 
Table 1 Grading of evidence [4] 
 
 
Rank Explanation Examples 
High Further research is very unlikely to 
change our confidence in the estimate 
of effect 
Randomized trials without serious 
limitations  
Well-performed observational 
studies with very large effects (or 
other qualifying factors) 
Moderate Further research is likely to have an 
important impact on our confidence in 
the estimate of effect and may change 
the estimate 
Randomized trials with serious 
limitations  
Well-performed observational 
studies yielding large effects 
Low Further research is very likely to have an 
important impact on our confidence in 
the estimate of effect and is likely to 
change the estimate 
Randomized trials with very serious 
limitations  
Observational studies without 
special strengths or important 
limitations 
Very low Any estimate of effect is very uncertain Randomized trials with very serious 
limitations and inconsistent results 
Observational studies with serious 
limitations  
Unsystematic clinical observations 
(e.g. case series or case reports) 
 
 
 
Table 2 Grading of recommendations [5] 
 
 
guidelines  
  Strong recommendation Weak recommendation 
Patients Most people in your 
situation would want the 
recommended course of 
action and only a small 
proportion would not 
The majority of people in 
your situation would want 
the recommended course 
of action, but many would 
not 
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Clinicians Most patients should 
receive the recommended 
course of action 
Recognize that different 
choices will be appropriate 
for different patients and 
that you must make 
greater effort to help each 
patient to arrive at a 
management decision 
consistent with his or her 
values and preferences; 
decision aids and shared 
decision making are 
particularly useful 
Policy makers The recommendation can 
be adopted as a policy in 
most situations 
Policy making will require 
substantial debate and 
involvement of many 
stakeholders 
 
The revised output from the group was reviewed by the BSG Endoscopy Committee 
on 13th of May 2015. A draft document and was then forwarded to the Royal College of 
Surgeons, Royal College of Radiologists, AUGIS, and the British Liver Trust. Comments from 
the professional and patient groups were received and considered by the GDG at a meeting 
held on the 27th September 2015.  In a number of areas it was recognised that whilst 
evidence was weak there was clear consensus among members of the GDG regarding the 
optimal clinical approach, and in this situation it was agreed by the contributors to make a 
strong recommendation. In keeping with BSG policy the guideline was then reviewed by the 
Society’s clinic services and standards committee, prior to submission for publication.  
Additional references were incorporated into the guideline following anonymised 
international peer review and the finalised recommendations were ratified by the GDG. 
 
5.0 General principles in the management of CBDS 
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(New 2016). It is recommended that patients diagnosed with CBDS are offered stone 
extraction if possible. Evidence of benefit is greatest for symptomatic patients. (Low quality 
evidence; strong recommendation). 
 
Primary ductal stones form de novo within the intra and extra hepatic ducts. They 
are most prevalent in Asian populations and give rise to the distinct clinical entity of 
recurrent pyogenic cholangitis,[1, 6, 7]. Secondary CBDS originate in the gallbladder and 
migrate into the bile duct via the cystic duct. They account for the majority of CBDS that 
occur in European patients. The following guideline focuses on the diagnosis and 
management of secondary CBDS. 
 
Data suggest the prevalence of CBDS in patients with symptomatic gallstones lies 
between 10-20%,[8, 9, 10, 11, 12, 13] though it should be noted that among patients where 
there is no clinical suspicion of ductal stones prior to surgery the incidence is significantly 
lower, and is typically reported to be less than 5%,[14, 15, 16, 17, 18, 19, 20]. 
Two to four percent of individuals with stones within the gallbladder will develop symptoms 
over the course of a year,[21, 22]. In comparison to gallbladder stones the natural history of 
CBDS is less well understood. Complications of CBDS are potentially life threatening and 
include pain, partial or complete biliary obstruction leading to obstructive jaundice, 
cholangitis, hepatic abscesses, pancreatitis and secondary biliary cirrhosis. Such problems 
can occur without warning,[23] but not all patients will experience difficulties secondary to 
CBDS.  Studies confirm that a number of patients will spontaneously pass ductal stones into 
their duodenum before or after laparoscopic cholecystectomy,[14, 24, 25]. That small 
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unsuspected stones can have a benign natural history is also supported by trials of selective 
IOC, where the incidence of CBDS related complications in patients who do not undergo 
cholangiography is reported to be low,[17, 18, 19, 20, 26]. 
 
This contrasts with a recent national cohort study that examined the outcomes of 
patients with proven CBDS at the time of cholecystectomy. In the GallRiks study,[27] 34200 
patients underwent an IOC and 3969 (11.6%) were found to have one or more CBDS. Of the 
3828 patients for whom there were adequate follow up data 594 (15.5%) received 
conservative treatment of their CBDS, whilst those remaining were recommended a 
treatment strategy that involved CBDS removal. Over a follow up period that varied from 0 
to 4 years 25.3% of patients in whom CBDS were left in situ experienced an unfavourable 
outcome (which was defined as pancreatitis, cholangitis, obstruction of the bile duct within 
30 days of surgery, or subsequent symptoms in association with proven CBDS on 
investigation). Only 12.7% of patients for whom some form of stone extraction was 
scheduled experienced an unfavourable outcome (odds ratio 0.44, 95% confidence interval 
0.35-0.55). The benefits of active treatment persisted for patients with CBDS less than 4 mm 
in diameter, where risk of unfavourable outcome with planned stone extraction was 8.9% vs. 
15.9% for patients treated conservatively (odds ratio 0.52, 95% confidence interval 0.34-
0.79).  
 
Therefore, in keeping with recent National Institute of Clinical Excellence (NICE) 
guidelines,[28] patients with CBDS should be offered stone extraction, assuming that they 
are fit enough to undergo treatment. It should be noted that there are no controlled studies 
examining the natural history of CBDS that are found incidentally in asymptomatic patients 
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being investigated for other medical problems. Patients should be made aware that advice 
to undergo stone extraction in this setting is based on evidence from symptomatic patients 
and expert opinion. 
 
 
6.0 Identifying individuals with CBDS 
 
6.1 Introduction 
 
Clinical presentations that warrant investigation for CBDS include epigastric or right 
upper quadrant pain,[29] especially if associated with jaundice,[30] and/or fever,[31]. CBDS 
should also be considered in patient with acute pancreatitis, where gallstones migrating to 
the common bile duct (CBD) are estimated to be a causal factor in up to 50% of cases,[32, 
33]. A minority of patients do not present with classical symptoms. As a consequence 
further tests are sometimes needed in patients with atypical abdominal symptoms that 
persist despite alternative forms of management,[28]. 
The following section examines the performance of the various tests available to the 
clinician and suggests an algorithm for investigation of patients with suspected CBDS. 
 
6.2 Role of trans-abdominal ultrasound and liver function tests  
 
(New 2016). Trans-abdominal ultrasound scanning (USS) and Liver function tests (LFTs) are 
recommended for patients with suspected CBDS. Normal results do not preclude further 
investigation if clinical suspicion remains high. (Low quality evidence; strong 
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recommendation). 
 
USS and LFTs are cheap, widely available and safe. They are therefore potentially 
useful tests for patients who have not undergone previous assessment for possible CBDS. In 
recent years a number of studies have examined the performance of one or other 
investigation.  Measuring diagnostic accuracy is difficult as many such studies are subject to 
bias,[34]. In addition  the reference standards for patients identified as being at high risk of 
having ductal stones  (i.e. endoscopic or surgical exploration), are rarely employed in 
patients thought to be at low risk of the condition. This makes it difficult to accurately 
establish the incidence of false negative results. This is important if a normal test means the 
diagnosis of CBDS is discounted.   However a recent Cochrane analysis,[34] has been 
performed based on studies that incorporated at least 6 months of clinical follow up for 
patients who did not undergo endoscopic or surgical exploration,[35, 36, 37, 38, 39]. 
Assuming a  pre-test probability of 0.095 (9.5%),  this analysis reported that 45 out of 100 
patients with a positive USS, variously defined in studies as presence of echogenic material 
in the CBD or CBD dilatation,  will have CBDS, rising to 85 out of 100 if pre-test probability is 
0.408 (40.8%). Conversely in patients with a negative USS, 3 out of 100 patients with a pre-
test probability of 0.095 (9.5%) will have CBDS vs. 17 out of 100 patients with a pre-test 
probability of 0.408 (40.8%). Analogous results for LFTs were dependent on the parameter 
and cut off points used but, if pre-test probability was 0.095 (9.5%), 32 out of 100 patients 
with an alkaline phosphatase of >125 IU/L would have CBDS vs. 2 out of 100 patients with an 
alkaline phosphatase that was <125 IU/L (noting the average alkaline phosphatase level in an 
adult population is between 50 and 170 IU/L). The performance of both USS and LFTs 
according to the pre-test probability of CBDS are summarised in table 3. 
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Table 3. Performance of USS and LFTs according to pre-test probability [34] 
Test (cut-off) Summary 
sensitivity 
(95% CI) 
Summary 
specificity 
(95% CI) 
Pre-test 
probability 
Positive post-
test probability 
(95% CI) 
Negative post-
test probability 
(95% CI) 
Ultrasound 0.73 (0.44 to 
0.90) 
0.91 (0.84 to 
0.95) 
0.095 0.45 (0.31 to 
0.60) 
0.03 (0.01 to 
0.07) 
0.408 0.85 (0.75 to 
0.91) 
0.17 (0.08 to 
0.33) 
0.658 0.94 (0.89 to 
0.97) 
0.37 (0.20 to 
0.58) 
Bilirubin (> 22.23 
μmol/L) 
0.84 (0.64 to 
0.94) 
0.91 (0.86 to 
0.94) 
0.095 0.49 (0.38 to 
0.59) 
0.02 (0.01 to 
0.04) 
Bilirubin (> twice 
the normal limit) 
0.42 (0.22 to 
0.63) 
0.97 (0.95 to 
0.99) 
0.095 0.63 (0.41 to 
0.81) 
0.06 (0.04 to 
0.08) 
Alkaline 
phosphatase (> 125 
IU/L) 
0.92 (0.74 to 
0.99) 
0.79 (0.74 to 
0.84) 
0.095 0.32 (0.26 to 
0.38) 
0.01 (0.00 to 
0.04) 
Alkaline 
phosphatase (> 
twice the normal 
limit) 
0.38 (0.19 to 
0.59) 
0.97 (0.95 to 
0.99) 
0.095 0.61 (0.38 to 
0.80) 
0.06 (0.05 to 
0.08) 
 
These results are helpful in formulating guidance, though it is important to note that 
clinicians routinely use both LFTs and USS together having first taken into account the pre-
test probability of stones, based on clinical history. This strategy is likely to be more effective 
than the isolated use of any one parameter,[40, 41, 42, 43, 44]. 
 
When there is a persistent suspicion of CBDS and results of LFTs and USS are non-
diagnostic further investigation may be necessary, as both USS and LFTs can be normal in 
people with CBDS. 
 
6.3 Magnetic resonance cholangiopancreatography and endoscopic ultrasound 
 
(New 2016). Magnetic resonance cholangiopancreatography (MRCP) and endoscopic 
ultrasound (EUS) are both recommended as highly accurate tests for identifying CBDS among 
patients with an intermediate probability of disease. MRCP predominates in this role, with 
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choice between the two modalities determined by individual suitability, availability of the 
relevant test, local expertise and patient acceptability. (Moderate quality evidence; strong 
recommendation). 
 
MRCP is produced by a heavily T2 weighted scan sequence which displays fluid, such 
as bile, as a high intensity bright signal on the resulting images. Solid material such as CBDS 
will appear as well defined, dark filling defects within the CBD. An echo-endoscope when 
positioned in the duodenal bulb uses high frequency sound waves to image the bile duct. 
When using EUS, CBDS appear as hyper-echoic foci, with characteristic acoustic shadowing. 
 
Studies that examine the performance of MRCP and/or EUS are heterogeneous with 
regards to patient selection and reference standards used. The potential for bias is also a 
concern (when, for example, researchers are aware of index test results when interpreting 
the reference standard).  Nonetheless, when analysis is restricted to published data that 
incorporate at least 6 months clinical follow up for patients who do not undergo duct 
exploration,[45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62] it is possible 
to demonstrate that both MRCP and EUS perform well. Specifically at a median pre-test 
probability for CBDS of 0.41 (41%), Cochrane systematic review data,[63] indicate that the 
summary sensitivity of EUS is 0.95, compared to 0.93 for MRCP, whilst summary specificity is 
0.97 for EUS compared to 0.96 for MRCP. These results are consistent with other published 
reviews,[64, 65]. It is important to note that the performance quoted does not apply to 
patients at low pre-test probability of stones (where the incidence of false positives can be 
expected to be higher) or patients with high pre-test probability of stones (where the 
clinician needs to be mindful of false negative results).  
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In keeping with the above observations studies that subject the same group of 
patients to both EUS and MRCP,[51, 53, 66] do not demonstrate clear superiority of one test 
over the other in relation to diagnosis of CBDS.   
 
Factors that favour EUS over MRCP are that it can be performed in the presence of 
intracranial metallic clips, cardiac pace makers, mechanical heart valves, claustrophobia and 
morbid obesity. Factors that favour MRCP over EUS include its wide availability, minimally 
invasive nature, ability to image the intra-hepatic ducts, cost effectiveness,[67] and 
suitability for patients with altered gastric or duodenal anatomy. In addition all images can 
be captured allowing for review by other clinicians at a later date. For these reasons, current 
NICE guidelines,[28] suggest that in most cases MRCP represents the safest and most 
acceptable test for patients, whilst acknowledging that appropriately skilled clinicians may 
choose to use EUS instead, and a minority of patients may need both investigations to 
ensure an accurate diagnosis. 
 
6.4 Computerised tomography 
 
Computerised tomography (CT) plays an important role in the identification and 
staging of malignant biliary obstruction but is not routinely used for the express purpose of 
detecting CBDS. Formal CT cholangiography, using excreted biliary contrast, is a useful and 
accurate diagnostic tool,[68, 69, 70, 71] for ductal stones but the required contrast agent has 
not been available in the UK since 2009. Recent studies using data from modern multi slice 
scanners suggest that standard contrasted CT scanning can also achieve reasonable 
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sensitivity (69-87%) and specificity (68-96%) for detecting CBDS,[72, 73, 74, 75] though 
diagnostic accuracy decreases considerably when calculi are small or of similar density to 
bile. In addition, CT exposes patients to the potential harm of ionising radiation and contrast 
injection.  
 
In current clinical practice CT is widely used to investigate patients who present with 
pain or other abdominal symptoms and it inevitable that a proportion of CBDS will be 
diagnosed this way. Sensitivity is best when radiologists look specifically for the presence of 
CBDS,[72]. The available evidence favours EUS or MRCP as the investigations of choice for 
CBDS, but CT is an important and appropriate diagnostic test for patients in whom features 
of CBDS and malignancy co-exist.   
 
6.5 Suggested algorithm for investigation of suspected CBD Stones 
 
(New 2016). It is suggested that patients with suspected CBDS who have not been previously 
investigated should undergo USS and LFTs. For patients with an intermediate probability of 
stones MRCP or EUS is recommended as a next step, unless the patient is proceeding directly 
to cholecystectomy supplemented by intra-operative cholangiography (IOC) or laparoscopic 
ultrasound (LUS). ERCP should be reserved for patients in whom preceding assessment 
indicates a need for endoscopic therapy. (Low quality evidence; weak recommendation). 
 
The probability of CBDS may be established on history, LFTs and USS. For example the  
American Society of Gastrointestinal Endoscopy (ASGE) indicate that in patients  with 
symptomatic gallbladder stones there is a high likelihood of CBDS if a calculus is visible in the 
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CBD on USS,  there are features of cholangitis or the patient presents with a combination of 
CBD  dilatation on USS and jaundice,[76]. Further investigation prior to scheduling 
endoscopic or surgical duct clearance is not mandated in this setting, though the need for CT 
to exclude pancreatobiliary malignancy should always be considered according to the clinical 
scenario. For other patients, likelihood will either be considered low (on the basis of normal 
LFTs and USS in the absence of a preceding clinical predictor such as cholangitis or gallstone 
pancreatitis), or intermediate. Among the latter group, a common scenario is pain with 
abnormal LFTs in the absence of duct dilatation on USS or vice versa. Further investigation of 
patients with a low or intermediate likelihood of CBDS is recommended prior to undertaking 
endoscopic or surgical bile duct clearance. A suggested pathway for investigation of 
suspected CBDS is described in figure 1. 
 
7.0 Endoscopic management of CBDS 
 
7.1 Introduction 
 
 
(New 2016). It is suggested that the BSG national standards framework for ERCP is 
implemented by service providers. (Very low quality evidence; weak recommendation). 
 
ERCP is a minimally invasive technique that is an effective treatment for CBDS,[77]. 
High rates of duct clearance are possible although the potential for serious adverse events is 
also recognised,[77, 78, 79]. In a large observational study conducted in England in 2004 
over 5% of patients undergoing ERCP experienced some form of complication, including 
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acute pancreatitis, bleeding, perforation and biliary sepsis,[80]. As such it is essential that 
the UK offers high quality training and that clinicians are able to maintain their skills in 
appropriately resourced facilities. Previous BSG guidelines made a number of 
recommendations in relation to this. These have recently been updated in the form of a 
national standards framework for ERCP,[81] published in 2014. This describes the minimum 
standards that service providers should adhere to, and also recommends a set of achievable 
standards that service providers should work toward implementing. 
 
In addition several important developments in ERCP practice have occurred in the 
last 10 years, which have the potential to improve success rates and minimize risk. These are 
described below.  
 
7.2 Anaesthesia supported endoscopic retrograde cholangiopancreatography 
 
 (New 2016). For selected patients, tolerability and likelihood of therapeutic success is higher 
if ERCP is performed with propofol sedation or general anaesthesia. It is recommended that 
hospitals looking after patients with CBDS should have ready and prompt access to 
anaesthesia supported ERCP. This can be an onsite service or provided by another ERCP unit 
as part of a clinical network. (Low quality evidence; strong recommendation). 
 
The great majority of ERCPs in the UK are performed under conscious sedation (i.e. 
IV benzodiazepine and opiate) and are generally well tolerated. However 14% of ERCPs 
performed under conscious sedation are reported to be poorly tolerated,[82] and this is an 
important cause of unsuccessful therapeutic ERCP,[83]. In the setting of CBDS this outcome 
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almost always necessitates further procedures, and delays in achieving clinical resolution. 
Anecdotally it may be an important cause of distress for individuals undergoing the 
procedure as was highlighted by the GDG’s patient representatives.  Failure to complete the 
procedure may also present a clinical risk.  The duration and complexity of ERCP often 
necessitates doses of benzodiazepine that are higher than routine diagnostic endoscopy. The 
national BSG audit of ERCP in 2004 showed that 33% of patients received > 5.5mg of 
midazolam, and approximately 8% of patients required the administration of reversal agents 
(flumazenil or naloxone),[80].  Although high quality evidence on the optimal form of 
sedation for ERCP is lacking,[84] most ERCP services in Western Europe and North America 
now utilize enhanced sedation (e.g. with propofol) or general anaesthesia as standard.  In 
2011, the BSG issued guidance in conjunction with the Royal College of Anaesthetists 
regarding the use of propofol sedation without the need for tracheal intubation in patients 
undergoing ERCP and other complex endoscopic procedures,[85]. These guidelines 
highlighted the minimum requirements for all endoscopic units wanting to deliver this 
service. In contrast to other health care systems, there is a lack of support in the UK for 
propofol-anaesthesia at endoscopy to be administered by non-anaesthetists. In patients 
with CBDS who require long and complex endoscopic procedures (e.g. cholangioscopy-
assisted electrohydraulic lithotripsy), a lack of enhanced sedation/general anaesthesia has 
been correlated with lack of therapeutic success,[86]. Propofol assisted ERCP in UK practice 
has recently been shown to be safe, and to be associated with high rates of ERCP success 
and patient satisfaction,[87]. 
 
In summary, clinician and patient opinion is in favour of wider availability of 
anaesthetist-assisted ERCP in the UK. The demand for propofol-assisted ERCP is likely to 
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increase, and should be specifically considered for complex cases of CBDS (e.g. intrahepatic 
ductal stones and cholangioscopy-assisted lithotripsy). General anaesthesia with 
endotracheal intubation is an alternative but is generally reserved for patients with 
anaesthetic issues independent of those related to ERCP per se (e.g. morbid obesity, 
airway/ventilation problems).  
 
 
7.3 Antibiotic use during endoscopic stone extraction 
 
(2008). It is suggested that patients should be managed in accordance with the BSG 
guidelines on antibiotic prophylaxis during endoscopy. (Very low quality evidence; weak 
recommendation). 
 
No changes have been made to the recommendation on antibiotic use published as 
part of the 2008 guidelines on CBDS,[1]. In the absence of specific risk factors for sepsis such 
as sclerosing cholangitis, communicating pancreatic cysts, hilar strictures, liver 
transplantation, cholangioscopy, or a failed attempt to drain an opacified bile duct it is 
suggested that prophylactic antibiotics can be safely avoided.  
 
7.4 Prophylaxis of post ERCP pancreatitis 
 
 (New 2016).  To reduce the risk of post ERCP pancreatitis (PEP) it is recommended that 
diclofenac or indomethacin (at a dose of 100 mg) should be administered rectally at the time 
of ERCP to all patients who do not have a contraindication to non-steroidal anti-
REVISED MARKED COPY, NOV 2016.  31 
inflammatory drugs (NSAIDs). (Moderate quality evidence; strong recommendation). 
 
 (New 2016). In patients with a high risk of PEP arising from repeated pancreatic duct 
cannulation, insertion of a pancreatic stent is suggested in addition to administration of 
rectal NSAID. (Moderate quality evidence; weak recommendation). 
 
  Acute pancreatitis is a well recognised complication of ERCP. The frequency of PEP 
varies considerably in the literature (from <1% to >20%), with 2-5% commonly reported. 
ERCP for bile duct stones does not confer an inherent increased risk of PEP above the 
baseline rate described for all forms of therapeutic ERCP.  However, the only way of 
definitively avoiding risk of PEP is by avoiding ERCP. This fact emphasizes the necessity of 
reserving ERCP as a therapeutic procedure for patients with proven bile duct stones, with 
the diagnosis made through modalities carrying little of no risk of PEP (e.g. USS, EUS, or 
MRCP as described above).  
 
 In people who require ERCP a number of prophylactic approaches may reduce the 
risks of PEP. The most important recent advance is in the use of prophylactic NSAIDs. High 
quality randomised control trials have unequivocally demonstrated the benefit of rectal 
NSAIDs (100mg indomethacin or diclofenac),[88, 89] and a recent ESGE practice guideline 
has recommended this in all patients undergoing ERCP, unless there is a 
contraindication,[90]. Short-term pancreatic duct stenting at ERCP reduces the risk of PEP in 
patients at increased risk of this complication by virtue of patient specific factors (young age, 
female sex, suspected Sphincter of Oddi dysfunction) or procedure specific factors (repeated 
pancreatic duct cannulation),[91] but also in mixed-risk populations which include those 
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undergoing ERCP for CBDS,[92]. Pancreatic duct cannulation or contrast-filling should be 
avoided at ERCP for CBDS wherever possible. If pancreatic duct cannulation repeatedly 
occurs (e.g. > 1 pancreatic wire passage) whilst attempting to gain biliary access, insertion of 
a 5F pancreatic stent can be considered,[90, 93]. This may both facilitate biliary access, and 
reduce the risk of PEP.  Importantly, failed attempts at stent placement may dramatically 
increase the risk of PEP, and so endoscopists who perform ERCP require appropriate training 
in this technique.  The optimum duration of placement is unknown but likely to be hours to 
days. As such ERCP units should reassess patients after pancreatic stent insertion to confirm 
spontaneous migration. Where spontaneous migration does not occur endoscopic removal 
is recommended,[90]. With the universal use of rectal NSAIDs, the additive benefit of 
pancreatic stents in the prevention of PEP is uncertain,[94]. 
 
7.5 Coagulopathy prior to sphincterotomy 
 
(2008 amended 2016).  It is recommended that patients undergoing biliary sphincterotomy 
for ductal stones have a full blood count (FBC) and international normalised ratio or 
prothrombin time (INR/PT) performed prior to their ERCP. If deranged clotting or 
thrombocytopenia is identified, subsequent management should conform to locally agreed 
guidelines. (Low quality evidence; strong recommendation). 
 
(New 2016). It is recommended that ERCP patients taking warfarin, anti-platelet treatment 
or a direct oral anticoagulant (DOAC) should be managed in accordance with the combined 
BSG and European Society of Gastrointestinal Endoscopy (ESGE) guidelines for patients 
undergoing endoscopy. (Low quality evidence; strong recommendation). 
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Abnormal clotting is a feature of biliary obstruction and parenchymal liver disease. 
Portal hypertension and severe sepsis can also result in thrombocytopenia. A recognised 
complication of biliary sphincterotomy is gastrointestinal haemorrhage but the point at 
which clotting abnormalities become an absolute contraindication to sphincterotomy cannot 
be asserted from the available evidence. Nonetheless attempts should be made to correct 
coagulopathy (including severe thrombocytopenia) before performing sphincterotomy, and 
if this is not possible initial therapy should involve a procedure with an inherently lower risk 
of bleeding such as endoscopic stenting. It is therefore recommended that patients 
undergoing biliary sphincterotomy for ductal stones should have a FBC and INR/PT 
performed prior to their ERCP. If deranged clotting is identified subsequent management 
should conform to locally agreed guidelines. 
 
For patients taking warfarin or anti platelet treatment the previous BSG 
guideline,[95] has been incorporated into a new BSG and ESGE guideline,[96]  which 
includes advice on patients prescribed DOACS. This class of drugs include factor 10a 
inhibitors (rivaroxaban, apixiban) and the thrombin inhibitor dabigatran. They benefit from 
fewer drug interactions than warfarin and have shorter half lives. However they cannot be 
readily reversed and INR cannot be used to assess bleeding risk,[97, 98, 99]. In the context of 
ERCP, management of antiplatelet and oral anticoagulant therapy will vary depending on the 
medication prescribed, the reason for its use, and on whether a high risk procedure 
(sphincterotomy) or low risk procedure (stenting) is being considered.  For patients taking 
warfarin, anti-platelet treatment or DOAC it is recommended that clinicians follow the 
management algorithms presented in the combined BSG and ESGE guidelines,[96]. These 
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guidelines advise that for endoscopic stenting alone, warfarin is continued and DOACS 
omitted on morning of procedure. For elective sphincterotomy, the guidelines suggest 
discontinuation of oral anticoagulation 2 to 5 days before intervention (depending on the 
anticoagulant used and patients renal function), with bridging therapy reserved for patients 
who have a high risk condition that is being treated with warfarin. In patients taking 
clopidogrel for a high risk condition, liaison with a cardiologist is advised prior to 
discontinuation. 
 
7.6 Role of access papillotomy 
 
 
(2008, amended 2016). Competency in access papillotomy is suggested for all endoscopists 
who perform ERCP. Training and subsequent mentorship should facilitate this. (Very low 
quality evidence; weak recommendation). 
 
 
Access papillotomy (previously described as precut or needle knife papillotomy) is a 
useful adjunct to endoscopic biliary cannulation in cases where access is difficult. Previous 
guidance has stressed the need for this technique to be restricted to those who are expert in 
its use, in view of a higher incidence of complication,[1]. The current guideline recognises 
that most clinicians performing ERCP will wish to employ access papillotomy in selected 
cases. It is therefore suggested that endoscopists who perform ERCP acquire sufficient 
experience during their period of training and mentorship to be able to identify when access 
papillotomy is indicated and safely perform the procedure. 
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7.7 Endoscopic papillary balloon dilation 
 
(New 2016). As an adjunct to biliary sphincterotomy endoscopic papillary balloon dilation 
(EPBD) is recommended as a technique to facilitate removal of large CBDS. (Low quality 
evidence; strong recommendation). 
 
(New 2016). EPBD without prior biliary sphincterotomy is associated with an increased risk of 
PEP but may be considered as an alternative to biliary sphincterotomy in selected patients, 
such as those with an uncorrected coagulopathy or difficult biliary access due to altered 
anatomy. If EPBD is performed without prior biliary sphincterotomy use of an 8mm diameter 
balloon is recommended. (Moderate quality evidence; strong recommendation). 
 
Studies over the last decade confirm EPBD for larger stones may be a safe and 
effective technique provided that dilation is performed following prior sphincterotomy,[100, 
101]. Systematic review of meta-analyses suggests that, in patients with large stones, EPBD 
with sphincterotomy can reduce the need for mechanical lithotripsy and may be associated 
with a lower rate of overall complications when compared to sphincterotomy alone,[102].  
Technical aspects of its use are important. Balloons greater than or equal to 10mm in 
diameter are usually used, though it is generally accepted that endoscopists should avoid 
dilating the sphincter beyond the diameter of the bile duct above. Most practitioners also 
advise caution in dilating to > 18 mm. In conjunction with balloon stone extraction, and 
mechanical lithotripsy, EPBD with prior sphincterotomy has an important role to play in the 
management of large CBDS,[76].  
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EPBD without prior sphincterotomy has also been been described in the 
management of CBDS. It fell out of general favour in view of an increased risk of pancreatitis, 
and poorer rates of stone clearance (with higher requirements for mechanical lithotripsy), 
when compared to sphincterotomy,[79, 103, 104]. Recently its role has been reconsidered, 
based on new meta-analyses,[105, 106, 107, 108], with evidence of similar rates of success 
and overall complication for the removal of small (<8mm) bile duct stones. Meta-analysis 
has also suggested relative risks of cholecystitis and recurrent CBDS may be lower in patients 
undergoing EPBD as opposed to biliary sphincterotomy,[108]. Most studies analysed used an 
8 mm diameter balloon regardless of CBD  diameter, with longer  duration balloon dilation (> 
1 minute to 5 minutes) being reported as the safest technique,[106]. It is important to note 
that the success rates quoted for EPBD in recent meta-analyses included patients 
randomised to EPBD who subsequently underwent rescue sphincterotomy. In addition there 
are a number of accepted contraindications to EPBD without prior sphincterotomy, including 
biliary strictures or malignancy, previous biliary surgery (other than cholecystectomy), 
cholangitis, pancreatitis, prior access papillotomy, and large CBDS (usually defined as 
>12mm),[105]. The GDG felt the increased risk of PEP remained an important limitation to 
recommending EPBD without prior sphincterotomy, but that it did have a role in routine 
clinical practice, and in particular could be considered where the risk of biliary 
sphincterotomy was increased, either because of coagulopathy that could not be readily 
corrected, or anatomical factors such as a papilla within a diverticulum. 
 
7.8 Role of Cholangioscopy 
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 (New 2016). It is recommended that cholangioscopy-guided electrohydraulic lithotripsy 
(EHL) or laser lithotripsy (LL) be considered when other endoscopic treatment options fail to 
achieve duct clearance. (Low quality evidence; strong recommendation). 
 
Per oral cholangioscopy allows endoscopic visualisation within the biliary tree and 
offers the potential to perform lithotripsy under direct vision utilising electrohydraulic or 
laser energy. Early studies used a “mother and baby” system, which required two operators, 
was technically challenging, and the cholangioscope broke easily. Whilst it was clear that 
stones could be treated effectively,[109] the above limitations restricted its widespread use 
and interest in the technique was limited. 
 
The introduction of new technologies has re-kindled interest in cholangioscopy.  The 
SpyGlass TM Legacy (Boston Scientific, Natick, MA, USA) cholangioscope was introduced in 
2006 and allows a single operator cholangioscopy (SOC) to be performed using a disposable 
cholangioscope, incorporating a fibre optic visualisation system, passed through the 
duodenoscope. Insertion of accessories through the scope may be a challenge and the fibre 
optic visualisation has also been criticised. These concerns may be addressed by a new 
Spyglass DSTM digital platform introduced in 2015. In direct per oral cholangioscopy, an ultra-
slim video upper GI endoscope is steered through a biliary sphincterotomy and into the bile 
duct. Whilst image quality is excellent, the major difficulty with this technique is stability of 
the endoscope within the bile duct due to the duodenal loop. When using this method the 
air or CO2 supply is switched off whilst cholangioscopy is being performed to reduce the risk 
of gas embolism. 
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The principle of EHL is the generation of a shock wave following the rapid thermal 
expansion of a fluid caused by a high voltage spark. A subsequent hydraulic pressure wave 
causes stone fragmentation. In LL, pulsed laser energy is focused on the stone. The thermal 
effect that is absorbed by the water contained in stones causes expansion and a shock wave 
that causes fragmentation. The delivery of such energy needs to be conducted under direct 
vision to ensure safety and precise targeting during fragmentation. 
  
In patients in whom clearance of CBDS has been unsuccessful (despite the use of 
techniques including mechanical lithotripsy and EPBD with prior sphincterotomy) SOC-
guided intraductal lithotripsy utilising both EHL and LL, results in very high stone clearance 
rates (73%–97%),[110, 111, 112]. Similarly high rates of stone clearance have been reported 
for direct cholangioscopy, albeit in smaller studies,[113]. Cholangioscopy is safe but 
cholangitis has been reported to occur more frequently at up to 9%,[112] necessitating the 
use of prophylactic antibiotics. Otherwise complications are comparable to conventional 
ERCP,[114]. Cholangioscopy guided lithotripsy is an important advance in the management 
of difficult CBDS and is a useful strategy for patients in whom standard techniques fail. 
 
8.0 Surgical management of common bile duct stones 
 
8.1 Introduction 
 
Surgical extraction of CBDS at the same time as (laparoscopic) cholecystectomy offers 
the opportunity to definitively treat gallstone related disease in a single stage procedure. 
Operator, patient, and procedure related factors all influence outcome.  
REVISED MARKED COPY, NOV 2016.  39 
 
8.2 Required facilities and personnel 
  
Though in a minority of patients there remains an important requirement for open 
surgical treatment, laparoscopic cholecystectomy has superseded open cholecystectomy as 
the operation of choice for symptomatic gallstones.  
 
Over 95% of gallbladders are now removed laparoscopically,[115] and more recently 
the technique of laparoscopic bile duct exploration (LBDE) has become more widely 
available.  LBDE requires (in most cases) a flexible choledochoscope together with light 
source and camera, and disposable instrumentation similar to that required for ERCP (e.g. 
baskets, balloons, stents).  Although open bile duct exploration can be carried out without a 
choledochoscope, because of the risks involved with blind instrumentation of the bile duct 
(i.e. perforation and traumatisation with increased risk of later stricture development), bile 
duct exploration should always be undertaken with a choledochoscope unless no alternative 
is available.  
 
There is a significant learning curve for laparoscopic bile duct surgery, both amongst 
surgeons and nursing staff,[116]. In the UK, centralisation of hepatopancreatobiliary 
resectional surgery into a defined number of units (currently 22) has allowed for the 
development of LBDE not only within those specialised units but also amongst benign upper 
gastrointestinal surgeons in non-resection centres.  
 
8.3 Investigation of the common bile duct prior to surgical exploration 
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(New 2016). IOC or LUS can be used to detect CBDS in patients who are suitable for surgical 
exploration or post-operative ERCP. Though not considered mandatory for all patients 
undergoing cholecystectomy, IOC or LUS is suggested for those patients who have an 
intermediate to high pre-test probability of CBDS and who have not had the diagnosis 
confirmed pre-operatively by USS, MRCP or EUS. (Low quality evidence; weak 
recommendation). 
 
 
The standard way of imaging the CBD intra-operatively is by IOC which involves trans-
cystic cannulation of the CBD with a fine catheter and direct injection of non-ionic contrast 
into the bile duct. Intra-operative laparoscopic ultrasound or LUS is an alternative modality 
but is not as widely available. Both tests show high sensitivity. The IOC rate in the UK varies 
widely between surgeons but overall is around 10%,[115]. The advantages of routine or 
selective IOC have been extensively debated in the literature and the reader is directed to 
the 2008 guidance on management of CBDS,[1] for a full description of the role of IOC at the 
time of laparoscopic cholecystectomy. Randomised control trials of IOC vs. no IOC in patients 
judged to be at low risk of CBDS,[17, 18, 19, 20, 26] suggest the use of preoperative results 
to select patients for further imaging is an acceptable strategy, although it is recognised that 
some clinicians may opt to perform an IOC in all patients undergoing cholecystectomy. 
 
8.4 Surgical bile duct exploration vs. endoscopic duct clearance 
 
(2016). It is  recommended that, in patients undergoing laparoscopic cholecystectomy, trans-
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cystic or trans-ductal laparoscopic bile duct exploration (LBDE) is an appropriate technique 
for CBDS removal.  There is no evidence of a difference in efficacy, mortality or morbidity 
when LBDE is compared to peri-operative ERCP, though LBDE is associated with a shorter 
hospital stay. It is recommended that the two approaches are considered equally valid 
treatment options. (High quality evidence; strong recommendation). 
 
(New 2016). It is suggested that training of surgeons in LBDE is to be encouraged in order to 
decrease the number of interventions required to manage CBDS. (Low quality evidence; weak 
recommendation). 
 
In patients undergoing laparoscopic cholecystectomy laparoscopic surgical 
exploration of the bile duct allows for single stage treatment of gallstone disease with 
removal of the gallbladder as part of the same procedure.  There are now a sufficient 
number of studies to determine that there is no significant difference in clinical 
outcomes,[77, 117, 118] between LBDE and laparoscopic cholecystectomy combined with 
pre or post-operative ERCP.  Studies have shown that single stage LBDE is associated with a 
reduction in overall hospital stay and cost when compared to the two-stage approach of 
ERCP and laparoscopic cholecystectomy,[119, 120]. It should be noted that there is some 
evidence to suggest that endoscopic sphincterotomy and stone clearance at the time of 
laparoscopic cholecystectomy is also cost saving, and may be associated with a lower 
incidence of complication when compared to pre-operative ERCP,[28, 121]. The GDG 
recognised intra-operative ERCP as a valid treatment option for CBDS but acknowledged the 
logistic challenges of providing this service on a routine basis.  The complications of surgical 
duct exploration are predominantly related to choledochotomy (bile duct leakage) and T-
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tube use (bile leakage, tube displacement). Pancreatitis is rare unless there has been ante-
grade instrumentation of the papilla,[122].  
 
T-tubes were traditionally inserted in open bile duct exploration because of the risk 
of bile leakage from the choledochotomy, which arose as a result of uncertainty regarding 
duct clearance (in the absence of choledochoscopy), or because of the presence of oedema 
and inflammation as a result of blind instrumentation of the duct.  LBDE with optical 
magnification, direct visualisation and more delicate instrumentation allows reduced trauma 
to the bile duct and has resulted in an increasing tendency to close the duct primarily. This 
avoids the morbidity associated with T-tubes which includes the discomfort of managing 10-
14 days with a T-tube through the abdominal wall, the risk of inadvertent early T-tube 
removal resulting in bile leakage, peritonitis and reoperation, and the need for post-
operative T-tube cholangiograms.  In addition a small number of bile ducts leaks occur 
following planned removal of the T-tube and this can necessitate repeat laparotomy.  Several 
studies have shown that primary duct closure without T-tube insertion is superior to 
planned T-tube insertion with reductions in hospital stay and a similar number of bile leaks 
and recurrent stones,[123]. In addition primary duct closure is associated with a shorter 
operative time and faster return to work of around 8 days,[124].   
 
      In terms of operative technique LBDE can be performed under image intensifier control 
or with the use of an ultra-thin choledochoscope (3 mm). It may involve a trans-cystic or 
trans-ductal approach.  The trans-cystic approach is more limited allowing retrieval of only 
small stones and poor access to the CHD.  Consequently the majority of surgeons use the 
trans-ductal approach directly through the CBD.  Regardless of exact technique used, the 
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high rates of duct clearance reported with LBDE,[119, 120, 125, 126, 127, 128, 129] can be 
increased to near 100% with the availability of intraductal piezoelectric or laser 
lithotripsy,[130]. Long-term results also appear favourable,[131, 132]. In patients undergoing 
laparoscopic cholecystectomy, trans-cystic or trans-ductal exploration of the CBD is therefore 
considered an appropriate technique for CBDS removal.  It  is estimated that only 20% of bile 
duct explorations are performed laparoscopically at the present time,[115] with findings 
from a 2005 survey of English hospitals suggesting less than one in three units treat patients 
using this technique,[133]. Given that ERCP and laparoscopic laparoscopic cholecystectomy 
involves two procedures (unless the former can be performed intra-operatively), it is 
suggested that surgeons are trained in LBCDE in order to decrease the number of 
interventions required to manage CBDS. 
 
9.0 Management of “difficult” ductal stones 
 
9.1 Introduction 
 
 (New 2016). Laparoscopic duct exploration and ERCP (supplemented by EPBD with prior 
sphincterotomy, mechanical lithotripsy or cholangioscopy where necessary) are highly 
successful in removing CBDS. It is recommended that percutaneous radiological stone 
extraction and open duct exploration should be reserved for the small number of patients in 
whom these techniques fail or are not possible. (Low quality evidence; strong 
recommendation). 
 
Extraction of ductal stones via an endoscopic biliary sphincterotomy or laparoscopic 
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route may be difficult for a variety of reasons. In most situations, size, shape and number of 
stones are the key determinants of whether extraction will be easy or not. The likelihood of 
successful extraction can also be reduced in patients who have altered anatomy as result of 
previous surgery (see section 10.5). Where standard stone extraction techniques 
supplemented by mechanical lithotripsy, EPBD with prior sphincterotomy, cholangioscopy 
(or, where available, extracorporeal shock wave lithotripsy) fail to remove stones the patient 
can be considered to have difficult stone disease. For the small number of individuals in 
whom problems persist despite deploying the above techniques percutaneous stone 
extraction and open duct exploration are sometimes necessary, and should be considered 
when less invasive options fail or are not possible. 
 
In this context, percutaneous CBDS extraction is usually achieved by establishing 
either a transhepatic, or less commonly transcholecystic biliary fistula through which 
catheter and cholangioscopic interventions are performed. Exact methods vary, but a typical 
procedure will involve balloon dilation of the biliary sphincter which allows stones to be 
pushed in an antegrade fashion into the duodenum, though larger calculi will require 
lithotripsy (either mechanical, electrohydraulic or laser). Completion rates are high but 
adverse events can occur with two recently published large series reporting major 
complications in 3.6% to 6.8% of patients,[134, 135]. 
 
9.2 Failed endoscopic cannulation of the common bile duct 
 
(New 2016). When endoscopic cannulation of the bile duct is not possible with standard 
techniques including access papillotomy, it is recommended that percutaneous or EUS guided 
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procedures can be considered as a means of facilitating subsequent ERCP (Low quality 
evidence; strong recommendation). 
 
 
Even the most skilled endoscopist will fail to achieve deep biliary cannulation in a 
minority of cases. Clinicians should be aware of the role of combined procedures to achieve 
access to biliary system. Typically these involve image guided percutaneous insertion of a 
catheter into the biliary system via the intrahepatic ducts or gallbladder, through which a 
guidewire is introduced into the duodenum. This can then be used by an endoscopist to 
achieve retrograde cannulation. 
 
More recently, endoscopic ultrasound guided biliary drainage has been described as 
an alternative to percutaneous intervention,[136]. Two main forms of EUS guided drainage 
have been reported. The first involves accessing the extra hepatic ducts, which is usually 
performed via the duodenum. The second involves accessing the intrahepatic ducts, which 
usually involves puncture of the left lobe of the liver via the stomach. Once biliary access has 
been achieved the endoscopist can then pass a wire to facilitate treatment, which can be 
performed in an antegrade fashion or combined with ERCP and retrograde therapy. A recent 
meta-analysis of (predominantly) retrospective cohort studies suggests this is a valid 
management option for biliary strictures,[137]. Whilst appropriately trained clinicians may 
wish to consider EUS guided access for selected cases of CBDS it should be noted that there 
are limited  data on its role in this setting and at present there are few centres that have the 
facilities and expertise to employ this approach routinely. 
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9.3 Stenting as treatment for CBDS 
 
 (2016). It is important that endoscopists ensure adequate biliary drainage is achieved in 
patients with CBDS that have not been extracted. The short-term use of a biliary stent 
followed by further endoscopy or surgery is recommended.  (Moderate quality evidence; 
strong recommendation). 
 
(2016). The use of a biliary stent as sole treatment for CBDS should be restricted to a selected 
group of patients with limited life expectancy and/or prohibitive surgical risk. (Moderate 
quality evidence; strong recommendation). 
 
Bacterial contamination of bile is a common finding in patients with CBDS and 
incomplete duct clearance may therefore place patients at risk of cholangitis,[138]. It is 
therefore important that endoscopists ensure adequate biliary drainage is achieved in 
patients with CBDS that cannot be retrieved. The short-term use of an endoscopic biliary 
stent followed by further ERCP or surgery has been shown to be a safe management option 
in this setting,[139].   
 
For patients over 70 years of age or with debilitating disease biliary stenting has also 
been examined as an alternative to endoscopic stone extraction,[139, 140]. The technique 
compares favourably with conventional stone extraction techniques, in terms of immediate 
success and complication rate. However at least a quarter of patients experience recurrent 
cholangitis during follow up. Long-term results are probably more favourable in those 
patients without a gallbladder,[140]. More recently a study from Italy looked at the 
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management of long-term stents in patients with CBDS that were difficult to remove by 
conventional means. Over a mean follow up period of 14 months, there was a 36% 
cholangitis rate in patients who had stents changed on demand with an associated mortality 
of 8%. Patients who had stents changed electively at 3 monthly intervals had an 8% 
cholangitis rate and 2% mortality,[141]. As such patients faced a high risk of complication or 
multiple interventions. 
 
 In light of the above findings biliary stenting is recommended as a means of ensuring 
adequate biliary drainage in patients for whom further therapy is planned. However stenting 
as definitive treatment for CBDS should be restricted to a very few patients who have limited 
life expectancy or are judged to be at prohibitive surgical risk. Clearance of bile duct stones 
should be considered the standard of care,[28] and patients should be referred to specialist 
centres for consideration of surgery or advanced endoscopic therapy if stones cannot be 
removed using standard stone extraction techniques. 
 
10.0 Management of CBDS in specific clinical settings 
 
10.1 Introduction 
 
Laparoscopic cholecystectomy and ERCP are now mature technologies and in some 
areas of practice there has been no major change in recommendations in comparison to the 
2008 guideline. Areas where advice has changed include treatment of acute gallstone 
pancreatitis. 
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10.2 Management of patients with and without a gallbladder 
 
(New 2016). Cholecystectomy is recommended for all patients with CBDS and gallbladder 
stones, unless there are specific reasons for considering surgery inappropriate. (High quality 
evidence; strong recommendation). 
Where operative risk is deemed prohibitive biliary sphincterotomy and endoscopic duct 
clearance alone is recommended as an acceptable alternative. (Very low quality evidence; 
weak recommendation). 
 
 (2008). Biliary sphincterotomy and endoscopic stone extraction is recommended as the 
primary form of treatment for patients with CBDS post cholecystectomy. (Low quality 
evidence; strong recommendation). 
 
 
For patients with gallbladder stones and stones in the CBD there is a risk of 
cholecystitis and/or stone migration following duct clearance. A Cochrane review published 
in 2007,[142] addressed the question as to whether prophylactic cholecystectomy should be 
offered patients whose gallbladder remains in situ after endoscopic sphincterotomy and CBD 
clearance. Systematic review identified five randomised trials involving 662 participants. The 
studies included both open cholecystectomy and exploration,[143, 144, 145] and 
laparoscopic cholecystectomy,[146, 147] as the surgical intervention of choice. Meta-
analysis indicated that over a follow up period that varied between an average of 17 months 
to over 5 years  mortality was higher in the wait and see group than in the prophylactic 
cholecystectomy group (14.1% vs. 7.9%; relative risk 1.78, 95% confidence interval 1.15 to 
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2.75) and that the benefit of surgery persisted when analysis was restricted to those studies 
that included patients at higher surgical risk, as defined by an American Society of 
Anaesthesiology (ASA) score of IV or V,[143, 144, 145, 148]. Secondary end points of 
recurrent pain, jaundice and cholangitis were also significantly more common in the wait 
and see group. Two more randomised trials have been published since this meta-analysis. In 
one prophylactic cholecystectomy after CBDS extraction was compared to a policy of leaving 
calculous gallbladders in situ. Prophylactic cholecystectomy reduced the incidence of 
subsequent cholecystitis but not cholangitis,[149]. However only 90 participants were 
included and the study was limited by significant cross over between the allocated 
treatment arms. In the second study,[150] 162 participants, all of whom were over the age 
of 70 years and had coexisting gallbladder stones, were randomised to wait and see or 
cholecystectomy after successful endoscopic duct clearance. A significant reduction in total 
biliary events (which included cholangitis) was seen in the group undergoing elective 
cholecystectomy.  
 
Uncertainty persists as to whether the recommendation to offer cholecystectomy to 
patients with gallbladder stones and CBDS should be extended to individuals with CBDS but 
an empty gallbladder on imaging. Several large observational studies have examined the 
importance of gallbladder status in Asian patients who have undergone successful 
endoscopic duct clearance,[151, 152, 153]. Over a period of follow up that varied from a 
median of 34 months,[151] to 15 years,[153] these studies reported recurrent CBDS in 15% 
to 23.7% of patients with residual gallbladder stones. This contrasted with patients who had 
an empty gallbladder in situ, where the reported incidence of recurrent CBDS was 
significantly lower at 5.9%,[152] to 11.3%,[153].  In contrast smaller studies of both 
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Asian,[154, 155, 156, 157] and European patients,[158, 159, 160] have not been able to 
clearly demonstrate a higher likelihood of recurrent CBDS following duct clearance in 
patients with gallbladder stones. However several suggest that patients with an empty 
gallbladder have a lower risk of cholecystitis and subsequent cholecystectomy,[155, 158, 
160]. Surgeons may therefore wish to discuss a wait and see approach with patients who 
have an empty gallbladder following duct clearance. 
 
Despite the benefits of cholecystectomy the operative risk for some patients will be 
judged prohibitive. Given that age and co-morbidity do not appear to have a significant 
impact on overall complication rates for ERCP,[161, 162, 163, 164] biliary sphincterotomy 
and endoscopic duct clearance alone is an acceptable alternative for this group. 
 
Whilst there is no formal comparison of endoscopic vs. surgical extraction of CBDS in 
patients who have undergone previous cholecystectomy, the minimally invasive nature of 
ERCP means that this remains the primary form of treatment in this setting and no change 
has been made to the recommendation for this category of patients. 
 
 
10.3 Management of cholangitis 
 
 (New 2016). Patients with acute cholangitis who fail to respond to antibiotic therapy or who 
have signs of septic shock require urgent biliary decompression. Endoscopic CBDS extraction 
and/or biliary stenting are recommended in this setting. If ERCP is not possible percutaneous 
radiological drainage can be considered as an alternative. (Moderate quality evidence; 
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strong recommendation). 
 
 
Historic data suggest the risks of emergency biliary surgery in older patients can be 
significant,[165, 166, 167, 168] and in the context of acute cholangitis the role of ERCP is 
now well established,[169]. High quality data on the optimal timing of ERCP in this setting 
are lacking but early intervention is likely to be beneficial. A recent prospective study of 199 
patients admitted to hospital with acute cholangitis found that for each day that ERCP was 
delayed, length of stay increased by 1.44 days (95% confidence interval 1.01 to 1.92). The 
study also identified an increased requirement for vasopressors in patients who had ERCP 
performed more than 72 hours after presentation,[170]. For patients with signs of septic 
shock or who are deteriorating despite appropriate antibiotic therapy, biliary decompression 
may need to be achieved urgently (i.e. within 24 hours of presentation).  As described in 
previous guidance in circumstances where ERCP fails or is unavailable, percutaneous biliary 
drainage is an alternative form of treatment.  
 
10.4 Acute gallstone pancreatitis 
 
(New 2016). Patients with pancreatitis of suspected or proven biliary origin who have 
associated cholangitis or persistent biliary obstruction are recommended to undergo biliary 
sphincterotomy and endoscopic stone extraction within 72 hours of presentation. (High 
quality evidence; strong recommendation). 
 
(New 2016). It is recommended that following gallstone pancreatitis early laparoscopic 
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cholecystectomy should be offered to all patients on whom it is safe to operate, as the most 
effective means to prevent recurrent episodes. (Moderate quality evidence, strong 
recommendation). 
 
(New 2016) In cases of mild acute gallstone pancreatitis it is suggested that cholecystectomy 
should be performed within 2 weeks of presentation and preferably during same admission. 
(Moderate quality evidence; weak recommendation). 
 
(New 2016).  It is recommended that patients with gallstone pancreatitis who do not require 
ERCP within 72h of presentation should be considered for elective ERCP and endoscopic 
sphincterotomy if there is evidence of retained CBDS on imaging or the patient is unsuitable 
for definitive treatment in the form of cholecystectomy. (Moderate quality evidence; strong 
recommendation). 
  
CBDS are a common cause of acute pancreatitis. A biliary aetiology for pancreatitis 
may be suggested by liver function test abnormalities; the presence of gallbladder stones, 
ductal stones or bile duct dilatation on imaging; or co-existent cholangitis. In such cases the 
timing and selection of patients for endoscopic stone extraction is important. Studies to date 
have produced conflicting evidence and guidelines have also supported varied approaches. 
This is reflected in the reported variation in clinical practice from extant guidelines,[171, 
172]. 
 
A recent Cochrane review,[173] has found no evidence that early routine biliary 
sphincterotomy +/- endoscopic stone extraction significantly affects mortality or 
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complications regardless of the severity of the pancreatitis. The analysis did support a 
strategy of early biliary sphincterotomy +/- endoscopic stone extraction in patients with 
cholangitis or biliary obstruction. 
 
There is heterogeneity in studies as to what constitutes “early” ERCP, with variation 
from <24hrs to <72hrs following admission.  There is no evidence to support ERCP within 24 
hours rather than ERCP within 72 hours. However no studies have been designed to answer 
this question. It is therefore recommended that patients with pancreatitis of suspected or 
proven biliary origin with associated biliary obstruction or cholangitis should undergo biliary 
sphincterotomy +/- endoscopic stone extraction within 72 hours of presentation. Within this 
group of patients clinicians should be alert to individuals with severe sepsis in whom optimal 
management may involve urgent ERCP within 24 hours, as described in section 10.3. 
Conversely it is recognized that a number of cases of jaundice without sepsis may resolve or 
improve significantly over a period of 24 to 72h. In this situation early ERCP can be avoided, 
though the clinician should consider additional imaging (MRCP, EUS, IOC or LUS) to exclude 
retained ductal stones and help decide whether biliary sphincterotomy is required to reduce 
the likelihood of future problems as described below. 
 
In patients with an in situ gallbladder, an episode of gallstone pancreatitis is 
associated with a significant risk of recurrent attacks as well as a smaller risk of biliary colic 
and cholecystitis,[174, 175, 176]. These risks can be reduced by removal of the gallbladder. 
Following mild gallstone pancreatitis laparoscopic cholecystectomy within 2 weeks of 
presentation and ideally during the same admission should be considered the preferred 
option,[177]. This may not be possible for patients with significant comorbidities or acute 
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severe pancreatitis, where removal of the gallbladder should be deferred until it is safe to 
operate. In patients who are unable to undergo cholecystectomy consideration should be 
given to elective biliary sphincterotomy. A recent systematic review of published studies and 
international guidelines suggests this significantly reduces the risk of recurrent pancreatitis 
but is a less effective strategy than cholecystectomy, particularly in relation to preventing 
other biliary complications,[178]. 
 
The greatest reduction in risk of recurrent events may be seen when patients 
undergo both sphincterotomy and cholecystectomy,[179]. As such, patients who require 
sphincterotomy and duct clearance in the context of acute gallstone pancreatitis should still 
be considered for subsequent laparoscopic cholecystectomy,[142] though there is currently 
insufficient evidence to recommend routine biliary sphincterotomy for all patients listed for 
laparoscopic cholecystectomy following mild acute gallstone pancreatitis. 
 
10.5 Stone extraction in patients with altered anatomy 
 
(New 2016). ERCP for CBDS extraction can be successfully performed in patients with Billroth 
II anatomy. Where ERCP with a duodenoscope is difficult use of a forward viewing scope is 
recommended. (Moderate quality evidence; weak recommendation). In cases where biliary 
sphincterotomy cannot be safely completed a limited sphincterotomy supplemented by EPBD 
is suggested as an alternative. (Low quality evidence; weak recommendation). 
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(New 2016). Patients with Roux-en-Y gastric bypass (RYGB) and CBDS should be referred to 
centres that are able to offer the advanced endsoscopic and surgical treatment options that 
are necessary for stone extraction. (Low quality evidence; weak recommendation). 
 
The endoscopic management of bile duct stones in patients with altered upper GI 
anatomy presents a significant challenge. The difficulties in reaching the papilla, accessing 
the bile duct and delivering appropriate therapy are factors that may reduce the likelihood 
of a successful procedure. The two common post-surgical states encountered are patients 
with Billroth II type gastrectomies and patients whom have undergone a gastric bypass with 
Roux –en-Y formation. The almost complete cessation of surgery for chronic peptic 
ulceration has resulted in a marked decline in number of patients with a Billroth II type 
gastrectomy whereas the number of patients undergoing obesity surgery (which includes 
RYGB) is rapidly increasing. This guideline will concentrate on these two clinical states. The 
subject, including technological considerations has recently been comprehensively 
reviewed,[180, 181]. 
Billroth II Gastrectomy 
Many experts believe that in the presence of an intact papilla the use of a side-viewing 
duodenoscope facilitates both cannulation and subsequent therapy because of the elevator 
and large accessory channel. A forward viewing endoscope however has advantages of 
flexibility and luminal visualisation that makes it possible to reach the papilla in Billroth II 
patients when an approach with a duodenoscope has failed. 
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The single RCT that has compared forward viewing endoscopes with conventional 
duodenoscopes demonstrated a higher success rate  with forward viewing endoscopes (87 
vs. 68%) and a higher complication rate with duodenoscopes (namely an 18% visceral 
perforation rate),[182]. This has not been confirmed by other reports that have described a 
perforation rate of 2.7-10%,[183, 184]. An approach of duodenoscope first followed by 
forward viewing endoscope if there is initial failure is a reasonable strategy. 
The “upside-down” (5 o’clock) orientation of the papilla when approached from the 
afferent limb after Billroth II gastrectomy requires a significant alteration in sphincterotomy 
technique. Successful outcomes can be achieved by using sphincterotomes that have been 
modified to alter the orientation of the cutting wire or by using conventional 
sphincterotomes that can be rotated. However in some cases safe, effective orientation of 
the cutting wire cannot be achieved. As a consequence it is not always possible to perform 
the full sphincterotomy that is required for successful removal of stones. Biliary 
sphincterotomy using a needle knife, with a straight plastic stent as a guide, is an alternative 
method that has been described in a number of series. Compared to EPBD it is reported to 
have equal efficacy,[185].  As discussed in section 7.7 there remain concerns about the risk 
of pancreatitis in patients undergoing EPBD without prior sphincterotomy. An approach that 
combines limited biliary sphincterotomy with a needle knife over a straight plastic biliary 
stent or guidewire, followed by EPBD and conventional stone extraction has been 
reported,[186]. It is becoming the method preferred by experts, and potentially combines 
ease of use, safety and efficacy. 
Roux-en-Y Gastric Bypass 
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The rapidly increasing health burden of obesity is driving an increase in bariatric 
surgery. Gallstone disease is a significant problem in the obese population and also in 
patients who have undergone weight loss procedures, of which the most commonly 
performed is a laparoscopic Roux-en-Y gastric bypass (RYGB).  
The long afferent limb of the RYGB that is deliberately fashioned at surgery 
effectively means that the only endoscopes that can be used in a conventional per-oral 
retrograde approach are enteroscopes with either a single or double balloon, or a spiral 
overtube. Selection and use of accessories is difficult, both because of the narrower working 
channels and length of the enteroscope. A large retrospective series compared enteroscopic 
techniques in 129 patients with Roux-en-Y reconstruction, of which 63 had post- RYGB 
anatomy with an intact papilla. Successful ERCP was achieved in 63% of these patients with 
a 12% complication rate,[187]. There was no significant difference in outcomes according to 
the enteroscopic technique used. 
Alternative techniques have been described that use the intact antroduodenal 
pathway from the excluded stomach to the papilla. These require a large gastrostomy 
through which a duodenoscope can be passed. The gastrostomy can be created by 
performing a long-limb enteroscopy to the stomach followed by a conventional 
percutaneous approach or by use of an interventional radiological technique with assistance 
from an EUS guided puncture from the gastric remnant. More recently the technique of EUS 
guided puncture from the gastric remnant followed by placement of a self-expanding 
lumen-apposing metal stent has been described. This allows for immediate per-oral access 
to the papilla. These are all complex procedures, reported in small series utilising 
endoscopic techniques that are highly specialised,[188, 189,190]. 
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Laparoscopically-assisted ERCP in post-RYGB patients is a technique that has been 
reported in larger numbers and the individual component techniques and skills are more 
readily available. A laparoscopic gastrostomy is created and at the same session ERCP is 
performed following which the gastrostomy is closed. A retrospective series from the US 
compared this technique to long-limb enteroscopy in 56 patients,[191]. The therapeutic 
success rate for laparoscopic-assisted ERCP was 100% vs. 59% in the enteroscopy group. 
There was no difference in hospital stay or complications in either group. Although there are 
organisational challenges with this technique, it is probably the best option currently and 
could be delivered by the majority of larger volume secondary care units. 
 
11.0 Implications for service organisation and training. 
 
Delivery of the achievable aims for ERCP service provision and training will require 
organisations to review the way their services are provided. Key performance indicators in 
the BSG standards framework,[75] include having sufficient capacity to deliver ERCP 52 
weeks a year; adequate interventional radiology support; access to anaesthesia supported 
ERCP and regular morbidity and mortality meetings that are able to demonstrate outcomes 
that meet minimum standards.  To achieve some of these key performance indicators will 
involve hospitals working collaboratively in the context of operational networks. Whilst 
additional resources will be needed in some areas, there is also the potential to avoid the 
costs incurred by delayed intervention, adverse events, repeat procedures and prolonged 
hospital stays. 
 
Similarly, if LBDE is to be made available to all patients who could potentially benefit 
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there will need to be sufficient numbers of trained surgeons to deliver this service and  
manpower planning will need to reflect this. 
 
Intra-operative ERCP is a valid alternative to LBDE but it is recognised that 
coordinating the relevant specialty teams and resources to deliver this on a routine basis 
within the National Health Service would require improved integration of medical and 
surgical gastroenterology services. 
 
12.0 Research recommendations 
 
Many of the recommendations contained within these guidelines are based on 
limited evidence, and conducting large scale head to head comparisons of different 
diagnostic and therapeutic strategies remains difficult. Opportunities for further research 
still exist in many areas, including: 
Studies that use adequate periods of clinical follow up to assess the diagnostic accuracy 
CBDS diagnosis using clinical, LFT and USS findings in combination. 
Studies of the natural history of CBDS, particularly in asymptomatic patients in whom 
extraction is not performed. 
Randomised control study of MRCP vs. EUS in the diagnosis of suspected CBDS. 
Studies to define minimum standards/key performance indicators for services offering 
endoscopic and surgical CBDS clearance. 
The features of a high quality service as measured by patients being treated for CBDS. 
Studies to establish the optimum treatment algorithm for removal of large CBDS. 
Studies to clarify the harm/benefit of routine IOC in patients with low risk of CBDS. 
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Studies to clarify the role of MPD stenting in patients receiving rectal NSAIDS. 
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14.0 Glossary of abbreviations 
ASA: American Society of Anesthesiology 
ASGE: American Society of Gastrointestinal Endoscopy 
AUGIS: Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland  
BSG: British Society of Gastroenterology 
CBDS: Common Bile Duct Stones 
CBD: Common Bile Duct  
CT: Computerised Tomography 
DOAC: Direct Acting Oral Anticoagulant 
EHL: Electrohydraulic Lithotripsy 
EPBD: Endoscopic Papillary Balloon Dilation  
ERCP: Endoscopic Retrograde Cholangiopancreatography 
ESGE: European Society of Gastrointestinal Endoscopy 
EUS: Endoscopic Ultrasound 
FBC: Full Blood Count 
GDG: Guideline Development Group  
INR/PT: International Normalised Ratio/Prothrombin Time 
IOC: Intra-Operative Cholangiogram 
LBDE: Laparoscopic Bile Duct Exploration 
LL: Laser Lithotripsy 
LUS: Laparoscopic Ultrasound 
MRCP: Magnetic Resonance Cholangiopancreatography 
NICE: National Institute of Clinical Excellence 
NSAIDS: Non Steroidal Anti-Inflammatory Drugs 
PEP: Post ERCP Pancreatitis 
RYGB: Roux-en-Y Gastric Bypass  
SOC: Single Operator Cholangioscopy 
USS: trans-abdominal Ultrasound Scan 
REVISED MARKED COPY, NOV 2016.  61 
 
15.0 References 
 
1 Williams EJ, Green J, Beckingham I, et al. Guidelines on the management of common bile 
duct stones (CBDS). Gut 2008;57:1004-21. 
2 Brouwers MC, Kho ME, Browman GP, et al. AGREE II: advancing guideline development, 
reporting and evaluation in health care. CMAJ 2010;182:E839-42. 
3 GRADE criteria. Accessed 01/06/2014 at http://www.gradeworkingpartygroup.org 
4 Brozek JL, Akl EA, Alonso-Coello P, et al. Grading quality of evidence and strength of 
recommendations in clinical practice guidelines. Part 1 of 3. An overview of the GRADE approach and 
grading quality of evidence about interventions. Allergy 2009;64:669-77. 
5 Brozek JL, Akl EA, Compalati E, et al. Grading quality of evidence and strength of 
recommendations in clinical practice guidelines part 3 of 3. The GRADE approach to developing 
recommendations. Allergy 2011;66:588-95. 
6 Tazuma S. Gallstone disease: Epidemiology, pathogenesis, and classification of biliary stones 
(common bile duct and intrahepatic). Best Pract Res Clin Gastroenterol 2006;20:1075-83. 
7 Tsui WM, Lam PW, Lee WK, et al. Primary hepatolithiasis, recurrent pyogenic cholangitis, and 
oriental cholangiohepatitis: a tale of 3 countries. Adv Anat Pathol 2011;18:318-28. 
8 Neuhaus H, Feussner H, Ungeheuer A, et al. Prospective evaluation of the use of endoscopic 
retrograde cholangiography prior to laparoscopic cholecystectomy. Endoscopy 1992;24:745-9. 
9 Saltzstein EC, Peacock JB, Thomas MD. Preoperative bilirubin, alkaline phosphatase and 
amylase levels as predictors of common duct stones. Surg Gynecol Obstet 1982;154:381-4. 
10 Lacaine F, Corlette MB, Bismuth H. Preoperative evaluation of the risk of common bile duct 
stones. Arch Surg 1980;115:1114-6. 
11 Houdart R, Perniceni T, Darne B, et al. Predicting common bile duct lithiasis: determination 
and prospective validation of a model predicting low risk. Am J Surg 1995;170:38-43. 
12 Welbourn CR, Mehta D, Armstrong CP, et al. Selective preoperative endoscopic retrograde 
cholangiography with sphincterotomy avoids bile duct exploration during laparoscopic 
cholecystectomy. Gut 1995;37:576-9. 
13 Videhult P, Sandblom G, Rasmussen IC. How reliable is intraoperative cholangiography as a 
method for detecting common bile duct stones? : A prospective population-based study on 1171 
patients. Surg Endosc 2009;23:304-12. 
14 Collins C, Maguire D, Ireland A, et al. A prospective study of common bile duct calculi in 
patients undergoing laparoscopic cholecystectomy: natural history of choledocholithiasis revisited. 
Ann Surg 2004;239:28-33. 
15 Nebiker CA, Baierlein SA, Beck S, et al. Is routine MR cholangiopancreatography (MRCP) 
justified prior to cholecystectomy? Langenbecks Arch Surg 2009;394:1005-10. 
16 Lill S, Rantala A, Pekkala E, et al. Elective laparoscopic cholecystectomy without routine 
intraoperative cholangiography: a retrospective analysis of 1101 consecutive cases. Scand J Surg 
2010;99:197-200. 
17 Hauer-Jensen M, Karesen R, Nygaard K, et al. Consequences of routine peroperative 
cholangiography during cholecystectomy for gallstone disease: a prospective, randomized study. 
World J Surg 1986;10:996-1002. 
18 Soper NJ, Dunnegan DL. Routine versus selective intra-operative cholangiography during 
laparoscopic cholecystectomy. World J Surg 1992;16:1133-40. 
19 Nies C, Bauknecht F, Groth C, et al. [Intraoperative cholangiography as a routine method? A 
prospective, controlled, randomized study]. Chirurg 1997;68:892-7. 
20 Khan OA, Balaji S, Branagan G, et al. Randomized clinical trial of routine on-table 
cholangiography during laparoscopic cholecystectomy. Br J Surg 2011;98:362-7. 
21 Attili AF, De Santis A, Capri R, et al. The natural history of gallstones: the GREPCO experience. 
REVISED MARKED COPY, NOV 2016.  62 
The GREPCO Group. Hepatology 1995;21:655-60. 
22 Halldestam I, Enell EL, Kullman E, et al. Development of symptoms and complications in 
individuals with asymptomatic gallstones. Br J Surg 2004;91:734-8. 
23 Cox MR, Budge JP, Eslick GD. Timing and nature of presentation of unsuspected retained 
common bile duct stones after laparoscopic cholecystectomy: a retrospective study. Surg Endosc 
2015;29:2033-8. 
24 Lefemine V, Morgan RJ. Spontaneous passage of common bile duct stones in jaundiced 
patients. Hepatobiliary Pancreat Dis Int 2011;10:209-13. 
25 Balandraud P, Biance N, Peycru T, et al. Fortuitous discovery of common bile duct stones: 
results of a conservative strategy. Gastroenterol Clin Biol 2008;32:408-12. 
26 Murison MS, Gartell PC, McGinn FP. Does selective peroperative cholangiography result in 
missed common bile duct stones? J R Coll Surg Edinb 1993;38:220-4. 
27 Moller M, Gustafsson U, Rasmussen F, et al. Natural course vs interventions to clear common 
bile duct stones: data from the Swedish Registry for Gallstone Surgery and Endoscopic Retrograde 
Cholangiopancreatography (GallRiks). JAMA Surg 2014;149:1008-13. 
28 NICE. Gallstone Disease: Diagnosis and management. Published October 2014. Accessible at 
https://www.nice.org.uk/guidance/cg188.  
29 Commissioning Guide: Gallstone Disease. London. Association of Upper Gastrointestinal 
Surgeons, 2013. 
30 Taylor A, Stapley S, Hamilton W. Jaundice in primary care: a cohort study of adults aged >45 
years using electronic medical records. Fam Pract 2012;29:416-20. 
31 Sheen AJ, Asthana S, Al-Mukhtar A, et al. Preoperative determinants of common bile duct 
stones during laparoscopic cholecystectomy. Int J Clin Pract 2008;62:1715-9. 
32 Corfield AP, Cooper MJ, Williamson RC. Acute pancreatitis: a lethal disease of increasing 
incidence. Gut 1985;26:724-9. 
33 Toh SK, Phillips S, Johnson CD. A prospective audit against national standards of the 
presentation and management of acute pancreatitis in the South of England. Gut 2000;46:239-43. 
34 Gurusamy KS, Giljaca V, Takwoingi Y, et al. Ultrasound versus liver function tests for diagnosis 
of common bile duct stones. Cochrane Database Syst Rev 2015;2:CD011548. 
35 Busel D, Espinoza Ugarte A, Osorio M, et al. [Ultrasonics in the diagnosis of 
choledocholithiasis]. Rev Med Chil 1989;117:40-1. 
36 Silverstein JC, Wavak E, Millikan KW. A prospective experience with selective 
cholangiography. Am Surg 1998;64:654-8; discussion 8-9. 
37 Kumar M, Prashad R, Kumar A, et al. Relative merits of ultrasonography, computed 
tomography and cholangiography in patients of surgical obstructive jaundice. 
Hepatogastroenterology 1998;45:2027-32. 
38 Admassie D, A HY, Denke A. Validity of ultrasonography in diagnosing obstructive jaundice. 
East Afr Med J 2005;82:379-81. 
39 Rickes S, Treiber G, Monkemuller K, et al. Impact of the operator's experience on value of 
high-resolution transabdominal ultrasound in the diagnosis of choledocholithiasis: a prospective 
comparison using endoscopic retrograde cholangiography as the gold standard. Scand J 
Gastroenterol 2006;41:838-43. 
40 Jovanovic P, Salkic NN, Zerem E, et al. Biochemical and ultrasound parameters may help 
predict the need for therapeutic endoscopic retrograde cholangiopancreatography (ERCP) in patients 
with a firm clinical and biochemical suspicion for choledocholithiasis. Eur J Intern Med 2011;22:e110-
4. 
41 Nathan T, Kjeldsen J, Schaffalitzky de Muckadell OB. Prediction of therapy in primary 
endoscopic retrograde cholangiopancreatography. Endoscopy 2004;36:527-34. 
42 Onken JE, Brazer SR, Eisen GM, et al. Predicting the presence of choledocholithiasis in 
patients with symptomatic cholelithiasis. Am J Gastroenterol 1996;91:762-7. 
43 Trondsen E, Edwin B, Reiertsen O, et al. Prediction of common bile duct stones prior to 
REVISED MARKED COPY, NOV 2016.  63 
cholecystectomy: a prospective validation of a discriminant analysis function. Arch Surg 
1998;133:162-6. 
44 Pourseidi B, Khorram-Manesh A. Triple non-invasive diagnostic test for exclusion of common 
bile ducts stones before laparoscopic cholecystectomy. World J Gastroenterol 2007;13:5745-9. 
45 Liu CL, Lo CM, Chan JK, et al. Detection of choledocholithiasis by EUS in acute pancreatitis: a 
prospective evaluation in 100 consecutive patients. Gastrointest Endosc 2001;54:325-30. 
46 Ang TLea. EUS Guided ERCP in patients with negative cross sectional imaging but high clinical 
probability of choledocholithiasis. Gastrointest Endosc 2012;1:AB203. 
47 Boraschi P, Gigoni R, Braccini G, et al. Detection of common bile duct stones before 
laparoscopic cholecystectomy. Evaluation with MR cholangiography. Acta Radiol 2002;43:593-8. 
48 Buscarini E, Tansini P, Vallisa D, et al. EUS for suspected choledocholithiasis: do benefits 
outweigh costs? A prospective, controlled study. Gastrointest Endosc 2003;57:510-8. 
49 Canto MI, Chak A, Stellato T, et al. Endoscopic ultrasonography versus cholangiography for 
the diagnosis of choledocholithiasis. Gastrointest Endosc 1998;47:439-48. 
50 Choo L. Prospective single blinded study of endoscopic ultrasound prior to endoscopic 
retrograde cholangiopanctreatography for patients for a positive intraoperative cholangiogram. 
Gastrointest Endosc 2012;1. 
51 de Ledinghen V, Lecesne R, Raymond JM, et al. Diagnosis of choledocholithiasis: EUS or 
magnetic resonance cholangiography? A prospective controlled study. Gastrointest Endosc 
1999;49:26-31. 
52 Fazel A. A comparision of the diagnostic accuracy of EUS and ERCP in identifying common 
bile duct stones. Gastrointest Endosc 2002;55. 
53 Fernandez-Esparrach G, Gines A, Sanchez M, et al. Comparison of endoscopic 
ultrasonography and magnetic resonance cholangiopancreatography in the diagnosis of 
pancreatobiliary diseases: a prospective study. Am J Gastroenterol 2007;102:1632-9. 
54 Gautier G, Pilleul F, Crombe-Ternamian A, et al. Contribution of magnetic resonance 
cholangiopancreatography to the management of patients with suspected common bile duct stones. 
Gastroenterol Clin Biol 2004;28:129-34. 
55 Guarise A, Baltieri S, Mainardi P, et al. Diagnostic accuracy of MRCP in choledocholithiasis. 
Radiol Med (Torino) 2005;109:239-51. 
56 Jendresen MB, Thorboll JE, Adamsen S, et al. Preoperative routine magnetic resonance 
cholangiopancreatography before laparoscopic cholecystectomy: a prospective study. Eur J Surg 
2002;168:690-4. 
57 Kohut M, Nowakowska-Dulawa E, Marek T, et al. Accuracy of linear endoscopic 
ultrasonography in the evaluation of patients with suspected common bile duct stones. Endoscopy 
2002;34:299-303. 
58 Miletic D, Uravic M, Mazur-Brbac M, et al. Role of magnetic resonance cholangiography in 
the diagnosis of bile duct lithiasis. World J Surg 2006;30:1705-12. 
59 Montariol T, Msika S, Charlier A, et al. Diagnosis of asymptomatic common bile duct stones: 
preoperative endoscopic ultrasonography versus intraoperative cholangiography--a multicenter, 
prospective controlled study. French Associations for Surgical Research. Surgery 1998;124:6-13. 
60 Ney MV, Maluf-Filho F, Sakai P, et al. Echo-endoscopy versus endoscopic retrograde 
cholangiography for the diagnosis of choledocholithiasis: the influence of the size of the stone and 
diameter of the common bile duct. Arq Gastroenterol 2005;42:239-43. 
61 Norton SA, Alderson D. Prospective comparison of endoscopic ultrasonography and 
endoscopic retrograde cholangiopancreatography in the detection of bile duct stones. Br J Surg 
1997;84:1366-9. 
62 Prat F, Amouyal G, Amouyal P, et al. Prospective controlled study of endoscopic 
ultrasonography and endoscopic retrograde cholangiography in patients with suspected common-
bileduct lithiasis. Lancet 1996;347:75-9. 
63 Giljaca V, Gurusamy KS, Takwoingi Y, et al. Endoscopic ultrasound versus magnetic resonance 
REVISED MARKED COPY, NOV 2016.  64 
cholangiopancreatography for common bile duct stones. Cochrane Database Syst Rev 
2015;2:CD011549. 
64 Ledro-Cano D. Suspected choledocholithiasis: endoscopic ultrasound or magnetic resonance 
cholangio-pancreatography? A systematic review. Eur J Gastroenterol Hepatol 2007;19:1007-11. 
65 McMahon CJ. The relative roles of magnetic resonance cholangiopancreatography (MRCP) 
and endoscopic ultrasound in diagnosis of common bile duct calculi: a critically appraised topic. 
Abdom Imaging 2008;33:6-9. 
66 Schmidt S, Chevallier P, Novellas S, et al. Choledocholithiasis: repetitive thick-slab single-shot 
projection magnetic resonance cholangiopancreaticography versus endoscopic ultrasonography. Eur 
Radiol 2007;17:241-50. 
67 Morris S, Gurusamy KS, Sheringham J, et al. Cost-Effectiveness Analysis of Endoscopic 
Ultrasound versus Magnetic Resonance Cholangiopancreatography in Patients with Suspected 
Common Bile Duct Stones. PLoS One 2015;10:e0121699. 
68 De Vargas Macciucca M, Lanciotti S, De Cicco ML, et al. Ultrasonographic and spiral CT 
evaluation of simple and complicated acute cholecystitis: diagnostic protocol assessment based on 
personal experience and review of the literature. Radiol Med 2006;111:167-80. 
69 Kondo S, Isayama H, Akahane M, et al. Detection of common bile duct stones: comparison 
between endoscopic ultrasonography, magnetic resonance cholangiography, and helical-computed-
tomographic cholangiography. Eur J Radiol 2005;54:271-5. 
70 Polkowski M, Palucki J, Regula J, et al. Helical computed tomographic cholangiography versus 
endosonography for suspected bile duct stones: a prospective blinded study in non-jaundiced 
patients. Gut 1999;45:744-9. 
71 Soto JA, Velez SM, Guzman J. Choledocholithiasis: diagnosis with oral-contrast-enhanced CT 
cholangiography. AJR Am J Roentgenol 1999;172:943-8. 
72 Anderson SW, Lucey BC, Varghese JC, et al. Accuracy of MDCT in the diagnosis of 
choledocholithiasis. AJR Am J Roentgenol 2006;187:174-80. 
73 Anderson SW, Rho E, Soto JA. Detection of biliary duct narrowing and choledocholithiasis: 
accuracy of portal venous phase multidetector CT. Radiology 2008;247:418-27. 
74 Kim CW, Chang JH, Lim YS, et al. Common bile duct stones on multidetector computed 
tomography: attenuation patterns and detectability. World J Gastroenterol 2013;19:1788-96. 
75 Tseng CW, Chen CC, Chen TS, et al. Can computed tomography with coronal reconstruction 
improve the diagnosis of choledocholithiasis? J Gastroenterol Hepatol 2008;23:1586-9. 
76 Maple JT, Ikenberry SO, Anderson MA, et al. The role of endoscopy in the management of 
choledocholithiasis. Gastrointest Endosc 2011;74:731-44. 
77 Dasari BV, Tan CJ, Gurusamy KS, et al. Surgical versus endoscopic treatment of bile duct 
stones. Cochrane Database Syst Rev 2013;12:CD003327. 
78 Gurusamy K, Sahay SJ, Burroughs AK, et al. Systematic review and meta-analysis of 
intraoperative versus preoperative endoscopic sphincterotomy in patients with gallbladder and 
suspected common bile duct stones. Br J Surg 2011;98:908-16. 
79 Weinberg BM, Shindy W, Lo S. Endoscopic balloon sphincter dilation (sphincteroplasty) 
versus sphincterotomy for common bile duct stones. Cochrane Database Syst Rev 2006:CD004890. 
80 Williams EJ, Taylor S, Fairclough P, et al. Are we meeting the standards set for endoscopy? 
Results of a large-scale prospective survey of endoscopic retrograde cholangio-pancreatograph 
practice. Gut 2007;56:821-9. 
81 Wilkinson M, Charnley R, Morris J, et al. ERCP, The Way Forward. A Standards Framework.  
2014. Accessible at  http://www.bsg.org.uk/clinical-guidance/endoscopy/ercp-the-way-forward-a-
standards-framework.html. 
82 Raymondos K, Panning B, Bachem I, et al. Evaluation of endoscopic retrograde 
cholangiopancreatography under conscious sedation and general anesthesia. Endoscopy 
2002;34:721-6. 
83 Church N, Periera S, Hatfield A, et al. Success of intial ERCP following therapeutic failure. Gut 
REVISED MARKED COPY, NOV 2016.  65 
2007;7 Suppl II:p A88. 
84 Garewal D, Powell S, Milan SJ, et al. Sedative techniques for endoscopic retrograde 
cholangiopancreatography. Cochrane Database Syst Rev 2012;6:CD007274. 
85 Guidance for the use of propofol sedation for adult patients undergoing endoscopic 
retrograde cholangiopancreatography (ERCP) and other complex upper GI procedures. On behalf of 
the Joint Royal College of Anaesthetists and British Society of Gastroenterology Working Party.  2011. 
86 Kalaitzakis E, Webster GJ, Oppong KW, et al. Diagnostic and therapeutic utility of single-
operator peroral cholangioscopy for indeterminate biliary lesions and bile duct stones. Eur J 
Gastroenterol Hepatol 2012;24:656-64. 
87 Joshi D, Paranandi B, Sayed GE, et al. Research: Experience of propofol sedation in a UK ERCP 
practice: lessons for service provision. Frontline Gastroenterol 2015 2015;6:32-7. 
88 Elmunzer BJ, Scheiman JM, Lehman GA, et al. A randomized trial of rectal indomethacin to 
prevent post-ERCP pancreatitis. N Engl J Med 2012;366:1414-22. 
89 Otsuka T, Kawazoe S, Nakashita S, et al. Low-dose rectal diclofenac for prevention of post-
endoscopic retrograde cholangiopancreatography pancreatitis: a randomized controlled trial. J 
Gastroenterol 2012;47:912-7. 
90 Dumonceau JM, Andriulli A, Elmunzer BJ, et al. Prophylaxis of post-ERCP pancreatitis: 
European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014. Endoscopy 
2014;46:799-815. 
91 Tarnasky PR, Palesch YY, Cunningham JT, et al. Pancreatic stenting prevents pancreatitis after 
biliary sphincterotomy in patients with sphincter of Oddi dysfunction. Gastroenterology 
1998;115:1518-24. 
92 Mazaki T, Mado K, Masuda H, et al. Prophylactic pancreatic stent placement and post-ERCP 
pancreatitis: an updated meta-analysis. J Gastroenterol 2014;49:343-55. 
93 Afghani E, Akshintala VS, Khashab MA, et al. 5-Fr vs. 3-Fr pancreatic stents for the prevention 
of post-ERCP pancreatitis in high-risk patients: a systematic review and network meta-analysis. 
Endoscopy 2014;46:573-80. 
94 Akbar A, Abu Dayyeh BK, Baron TH, et al. Rectal nonsteroidal anti-inflammatory drugs are 
superior to pancreatic duct stents in preventing pancreatitis after endoscopic retrograde 
cholangiopancreatography: a network meta-analysis. Clin Gastroenterol Hepatol 2013;11:778-83. 
95 Veitch AM, Baglin TP, Gershlick AH, et al. Guidelines for the management of anticoagulant 
and antiplatelet therapy in patients undergoing endoscopic procedures. Gut 2008;57:1322-9. 
96 Veitch AM, Vanbiervliet G, Gershlick AH, et al. Endoscopy in patients on antiplatelet or 
anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) 
and European Society of Gastrointestinal Endoscopy (ESGE) guidelines. Gut 2016;65:374-89. 
97 Baron TH, Kamath PS, McBane RD. New anticoagulant and antiplatelet agents: a primer for 
the gastroenterologist. Clin Gastroenterol Hepatol 2014;12:187-95. 
98 Abraham NS, Castillo DL. Novel anticoagulants: bleeding risk and management strategies. 
Curr Opin Gastroenterol 2013;29:676-83. 
99 Desai J, Granger CB, Weitz JI, et al. Novel oral anticoagulants in gastroenterology practice. 
Gastrointest Endosc 2013;78:227-39. 
100 Ersoz G, Tekesin O, Ozutemiz AO, et al. Biliary sphincterotomy plus dilation with a large 
balloon for bile duct stones that are difficult to extract. Gastrointest Endosc 2003;57:156-9. 
101 Heo JH, Kang DH, Jung HJ, et al. Endoscopic sphincterotomy plus large-balloon dilation versus 
endoscopic sphincterotomy for removal of bile-duct stones. Gastrointest Endosc 2007;66:720-6; quiz 
68, 71. 
102 Kim TH, Kim JH, Seo DW, et al. International consensus guidelines for endoscopic papillary 
large-balloon dilation. Gastrointest Endosc 2016;83:37-47. 
103 Freeman ML, DiSario JA, Nelson DB, et al. Risk factors for post-ERCP pancreatitis: a 
prospective, multicenter study. Gastrointest Endosc 2001;54:425-34. 
104 Freeman ML, Guda NM. Prevention of post-ERCP pancreatitis: a comprehensive review. 
REVISED MARKED COPY, NOV 2016.  66 
Gastrointest Endosc 2004;59:845-64. 
105 Testoni PA, Mariani A, Aabakken L, et al. Papillary cannulation and sphincterotomy 
techniques at ERCP: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. 
Endoscopy 2016;48:657-83. 
106 Liao WC, Tu YK, Wu MS, et al. Balloon dilation with adequate duration is safer than 
sphincterotomy for extracting bile duct stones: a systematic review and meta-analyses. Clin 
Gastroenterol Hepatol 2012;10:1101-9. 
107 Liu Y, Su P, Lin S, et al. Endoscopic papillary balloon dilatation versus endoscopic 
sphincterotomy in the treatment for choledocholithiasis: a meta-analysis. J Gastroenterol Hepatol 
2012;27:464-71. 
108 Zhao HC, He L, Zhou DC, et al. Meta-analysis comparison of endoscopic papillary balloon 
dilatation and endoscopic sphincteropapillotomy. World J Gastroenterol 2013;19:3883-91. 
109 Neuhaus H, Hoffmann W, Zillinger C, et al. Laser lithotripsy of difficult bile duct stones under 
direct visual control. Gut 1993;34:415-21. 
110 Chen YK, Parsi MA, Binmoeller KF, et al. Single-operator cholangioscopy in patients requiring 
evaluation of bile duct disease or therapy of biliary stones (with videos). Gastrointest Endosc 
2011;74:805-14. 
111 Maydeo A, Kwek BE, Bhandari S, et al. Single-operator cholangioscopy-guided laser 
lithotripsy in patients with difficult biliary and pancreatic ductal stones (with videos). Gastrointest 
Endosc 2011;74:1308-14. 
112 Kalaitzakis E, Sturgess R, Kaltsidis H, et al. Diagnostic utility of single-user peroral 
cholangioscopy in sclerosing cholangitis. Scand J Gastroenterol 2014;49:1237-44. 
113 Moon JH, Ko BM, Choi HJ, et al. Direct peroral cholangioscopy using an ultra-slim upper 
endoscope for the treatment of retained bile duct stones. Am J Gastroenterol 2009;104:2729-33. 
114 Sethi A, Chen YK, Austin GL, et al. ERCP with cholangiopancreatoscopy may be associated 
with higher rates of complications than ERCP alone: a single-center experience. Gastrointest Endosc 
2011;73:251-6. 
115 Surgical Workload and Outcomes Audit Database (SWORD). Accessed 04/2015 at 
http://www.augis.org/sword/database. 
116 Moore MJ, Bennett CL. The learning curve for laparoscopic cholecystectomy. The Southern 
Surgeons Club. Am J Surg 1995;170:55-9. 
117 Kenny R, Richardson J, McGlone ER, et al. Laparoscopic common bile duct exploration versus 
pre or post-operative ERCP for common bile duct stones in patients undergoing cholecystectomy: is 
there any difference? Int J Surg 2014;12:989-93. 
118 Alexakis  N, Connor S. Meta-analysis of one- vs. two-stage laparoscopic/endoscopic 
management of common bile duct stones. HPB (Oxford) 2012;14(4):254-259. 
119 Rhodes M, Sussman L, Cohen L, et al. Randomised trial of laparoscopic exploration of 
common bile duct versus postoperative endoscopic retrograde cholangiography for common bile 
duct stones. Lancet 1998;351:159-61. 
120 Cuschieri A, Lezoche E, Morino M, et al. E.A.E.S. multicenter prospective randomized trial 
comparing two-stage vs single-stage management of patients with gallstone disease and ductal 
calculi. Surg Endosc 1999;13:952-7. 
121 Gurusamy K, Wilson E, Burroughs AK, et al. Intra-operative vs pre-operative endoscopic 
sphincterotomy in patients with gallbladder and common bile duct stones: cost-utility and value-of-
information analysis. Appl Health Econ Health Policy 2012;10:15-29. 
122 Tranter SE, Thompson MH. Comparison of endoscopic sphincterotomy and laparoscopic 
exploration of the common bile duct. Br J Surg 2002;89:1495-504. 
123 Zhang HW, Chen YJ, Wu CH, et al. Laparoscopic common bile duct exploration with primary 
closure for management of choledocholithiasis: a retrospective analysis and comparison with 
conventional T-tube drainage. Am Surg 2014;80:178-81. 
124 Gurusamy KS, Koti R, Davidson BR. T-tube drainage versus primary closure after laparoscopic 
REVISED MARKED COPY, NOV 2016.  67 
common bile duct exploration. Cochrane Database Syst Rev 2013;6:CD005641. 
125 Petelin JB. Laparoscopic common bile duct exploration. Surg Endosc 2003;10:10. 
126 DePaula AL, Hashiba K, Bafutto M. Laparoscopic management of choledocholithiasis. Surg 
Endosc 1994;8:1399-403. 
127 Franklin ME, Jr., Pharand D, Rosenthal D. Laparoscopic common bile duct exploration. Surg 
Laparosc Endosc 1994;4:119-24. 
128 Berci G, Morgenstern L. Laparoscopic management of common bile duct stones. A multi-
institutional SAGES study. Society of American Gastrointestinal Endoscopic Surgeons. Surg Endosc 
1994;8:1168-74; discussion 74-5. 
129 Martin DJ, Vernon DR, Toouli J. Surgical versus endoscopic treatment of bile duct stones. 
Cochrane Database Syst Rev 2006:CD003327. 
130 Varban O, Assimos D, Passman C, et al. Video. Laparoscopic common bile duct exploration 
and holmium laser lithotripsy: a novel approach to the management of common bile duct stones. 
Surg Endosc 2010;24:1759-64. 
131 Waage A, Stromberg C, Leijonmarck CE, et al. Long-term results from laparoscopic common 
bile duct exploration. Surg Endosc 2003;17:1181-5. Epub 2003 May 13. 
132 Riciardi R, Islam S, Canete JJ, et al. Effectiveness and long-term results of laparoscopic 
common bile duct exploration. Surg Endosc 2003;17:19-22. Epub 2002 Oct 29. 
133 Williams EJ and the Steering Committee, BSG Audit of ERCP. Diagnosis and management of 
suspected common bile duct stones in patients fit for cholecystectomy: a survey of 5 UK regions. Gut 
2006;55:A94 (361) Abstract. 
134 Ozcan N, Kahriman G, Mavili E. Percutaneous transhepatic removal of bile duct stones: 
results of 261 patients. Cardiovasc Intervent Radiol 2012;35:890-7. 
135 Kint JF, van den Bergh JE, van Gelder RE, et al. Percutaneous treatment of common bile duct 
stones: results and complications in 110 consecutive patients. Dig Surg 2015;32:9-15. 
136 Giovannini M, Moutardier V, Pesenti C, et al. Endoscopic ultrasound-guided bilioduodenal 
anastomosis: a new technique for biliary drainage. Endoscopy 2001;33:898-900. 
137 Khan MA, Akbar A, Baron TH, et al. Endoscopic Ultrasound-Guided Biliary Drainage: A 
Systematic Review and Meta-Analysis. Dig Dis Sci 2016;61:684-703. 
138 Maluenda F, Csendes A, Burdiles P, et al. Bacteriological study of choledochal bile in patients 
with common bile duct stones, with or without acute suppurative cholangitis. 
Hepatogastroenterology 1989;36:132-5. 
139 Bergman JJ, Rauws EA, Tijssen JG, et al. Biliary endoprostheses in elderly patients with 
endoscopically irretrievable common bile duct stones: report on 117 patients. Gastrointest Endosc 
1995;42:195-201. 
140 Chopra KB, Peters RA, O'Toole PA, et al. Randomised study of endoscopic biliary 
endoprosthesis versus duct clearance for bileduct stones in high-risk patients. Lancet 1996;348:791-
3. 
141 Di Giorgio P, Manes G, Grimaldi E, et al. Endoscopic plastic stenting for bile duct stones: stent 
changing on demand or every 3 months. A prospective comparison study. Endoscopy 2013;45:1014-
7. 
142 McAlister VC, Davenport E, Renouf E. Cholecystectomy deferral in patients with endoscopic 
sphincterotomy. Cochrane Database Syst Rev 2007:CD006233. 
143 Hammarstrom LE, Holmin T, Stridbeck H, et al. Long-term follow-up of a prospective 
randomized study of endoscopic versus surgical treatment of bile duct calculi in patients with 
gallbladder in situ. Br J Surg 1995;82:1516-21. 
144 Targarona EM, Ayuso RM, Bordas JM, et al. Randomised trial of endoscopic sphincterotomy 
with gallbladder left in situ versus open surgery for common bileduct calculi in high-risk patients. 
Lancet 1996;347:926-9. 
145 Suc B, Escat J, Cherqui D, et al. Surgery vs endoscopy as primary treatment in symptomatic 
patients with suspected common bile duct stones: a multicenter randomized trial. French 
REVISED MARKED COPY, NOV 2016.  68 
Associations for Surgical Research. Arch Surg 1998;133:702-8. 
146 Boerma D, Rauws EA, Keulemans YC, et al. Wait-and-see policy or laparoscopic 
cholecystectomy after endoscopic sphincterotomy for bile-duct stones: a randomised trial. Lancet 
2002;360:761-5. 
147 Lau JY, Leow CK, Fung TM, et al. Cholecystectomy or gallbladder in situ after endoscopic 
sphincterotomy and bile duct stone removal in Chinese patients. Gastroenterology 2006;130:96-103. 
148 American Society of Anesthesiologists ASA Physical Classification System. Accessed 
23/08/2016 at https://www.asahq.org/resources/clinical-information/asa-physical-status-
classification-system. 
149 Heo J, Jung MK, Cho CM. Should prophylactic cholecystectomy be performed in patients with 
concomitant gallstones after endoscopic sphincterotomy for bile duct stones? Surg Endosc 
2015;29:1574-9. 
150 Zargar SA, Mushtaq M, Beg MA, et al. Wait-and-see policy versus cholecystectomy after 
endoscopic sphincterotomy for bile-duct stones in high-risk patients with co-existing gallbladder 
stones: a prospective randomised trial. Arab J Gastroenterol 2014;15:24-6. 
151 Tsai TJ, Lai KH, Lin CK, et al. The relationship between gallbladder status and recurrent biliary 
complications in patients with choledocholithiasis following endoscopic treatment. J Chin Med Assoc 
2012;75:560-6. 
152 Tsujino T, Kawabe T, Komatsu Y, et al. Endoscopic papillary balloon dilation for bile duct 
stone: immediate and long-term outcomes in 1000 patients. Clin Gastroenterol Hepatol 2007;5:130-
7. 
153 Ando T, Tsuyuguchi T, Okugawa T, et al. Risk factors for recurrent bile duct stones after 
endoscopic papillotomy. Gut 2003;52:116-21. 
154 Lee JK, Ryu JK, Park JK, et al. Risk factors of acute cholecystitis after endoscopic common bile 
duct stone removal. World J Gastroenterol 2006;12:956-60. 
155 Cui ML, Cho JH, Kim TN. Long-term follow-up study of gallbladder in situ after endoscopic 
common duct stone removal in Korean patients. Surg Endosc 2013;27:1711-6. 
156 Kageoka M, Watanabe F, Maruyama Y, et al. Long-term prognosis of patients after 
endoscopic sphincterotomy for choledocholithiasis. Dig Endosc 2009;21:170-5. 
157 Kwon SK, Lee BS, Kim NJ, et al. Is cholecystectomy necessary after ERCP for bile duct stones 
in patients with gallbladder in situ? Korean J Intern Med 2001;16:254-9. 
158 Costamagna G, Tringali A, Shah SK, et al. Long-term follow-up of patients after endoscopic 
sphincterotomy for choledocholithiasis, and risk factors for recurrence. Endoscopy 2002;34:273-9. 
159 Adamek HE, Kudis V, Jakobs R, et al. Impact of gallbladder status on the outcome in patients 
with retained bile duct stones treated with extracorporeal shockwave lithotripsy. Endoscopy 
2002;34:624-7. 
160 Hammarstrom LE, Holmin T, Stridbeck H. Endoscopic treatment of bile duct calculi in patients 
with gallbladder in situ: long-term outcome and factors. Scand J Gastroenterol 1996;31:294-301. 
161 Freeman ML, Nelson DB, Sherman S, et al. Complications of endoscopic biliary 
sphincterotomy. N Engl J Med 1996;335:909-18. 
162 Masci E, Toti G, Mariani A, et al. Complications of diagnostic and therapeutic ERCP: a 
prospective multicenter study. Am J Gastroenterol 2001;96:417-23. 
163 Mitchell RM, O'Connor F, Dickey W. Endoscopic retrograde cholangiopancreatography is safe 
and effective in patients 90 years of age and older. J Clin Gastroenterol 2003;36:72-4. 
164 Garcia-Cano Lizcano J, Gonzalez Martin JA, Taberna Arana L, et al. [Therapeutic biliary 
endoscopy in patients over 90 years of age]. An Med Interna 2002;19:409-11. 
165 Lygidakis NJ. Operative risk factors of cholecystectomy-choledochotomy in the elderly. Surg 
Gynecol Obstet 1983;157:15-9. 
166 Siegel JH, Kasmin FE. Biliary tract diseases in the elderly: management and outcomes. Gut 
1997;41:433-5. 
167 Gonzalez JJ, Sanz L, Grana JL, et al. Biliary lithiasis in the elderly patient: morbidity and 
REVISED MARKED COPY, NOV 2016.  69 
mortality due to biliary surgery. Hepatogastroenterology 1997;44:1565-8. 
168 Hacker KA, Schultz CC, Helling TS. Choledochotomy for calculous disease in the elderly. Am J 
Surg 1990;160:610-2; discussion 3. 
169 Lai EC, Mok FP, Tan ES, et al. Endoscopic biliary drainage for severe acute cholangitis. N Engl J 
Med 1992;326:1582-6. 
170 Hou LA, Laine L, Motamedi N, et al. Optimal Timing of Endoscopic Retrograde 
Cholangiopancreatography in Acute Cholangitis. J Clin Gastroenterol 2016. 
DOI:10.1097/MCG.0000000000000763. [epub ahead of print] 
171 Barnard J, Siriwardena AK. Variations in implementation of current national guidelines for the 
treatment of acute pancreatitis: implications for acute surgical service provision. Ann R Coll Surg Engl 
2002;84:79-81. 
172 Mofidi R, Madhavan KK, Garden OJ, et al. An audit of the management of patients with acute 
pancreatitis against national standards of practice. Br J Surg 2007;94:844-8. 
173 Tse F, Yuan Y. Early routine endoscopic retrograde cholangiopancreatography strategy versus 
early conservative management strategy in acute gallstone pancreatitis. Cochrane Database Syst 
Rev;5:CD009779. 
174 Alimoglu O, Ozkan OV, Sahin M, et al. Timing of cholecystectomy for acute biliary 
pancreatitis: outcomes of cholecystectomy on first admission and after recurrent biliary pancreatitis. 
World J Surg 2003;27:256-9. 
175 Hernandez V, Pascual I, Almela P, et al. Recurrence of acute gallstone pancreatitis and 
relationship with cholecystectomy or endoscopic sphincterotomy. Am J Gastroenterol 2004;99:2417-
23. 
176 van Baal MC, Besselink MG, Bakker OJ, et al. Timing of cholecystectomy after mild biliary 
pancreatitis: a systematic review. Ann Surg 2012;255:860-6. 
177 da Costa DW, Bouwense SA, Schepers NJ, et al. Same-admission versus interval 
cholecystectomy for mild gallstone pancreatitis (PONCHO): a multicentre randomised controlled trial. 
Lancet 2015;386:1261-8. 
178 da Costa DW, Schepers NJ, Romkens TE, et al. Endoscopic sphincterotomy and 
cholecystectomy in acute biliary pancreatitis. Surgeon 2015;14:99-108. 
179 Mustafa A, Begaj I, Deakin M, et al. Long-term effectiveness of cholecystectomy and 
endoscopic sphincterotomy in the management of gallstone pancreatitis. Surg Endosc 2014;28:127-
33. 
180 Enestvedt BK, Kothari S, Pannala R, et al. Devices and techniques for ERCP in the surgically 
altered GI tract. Gastrointest Endosc 2016;83:1061-75. 
181 Gomez V, Petersen BT. Endoscopic Retrograde Cholangiopancreatography in Surgically 
Altered Anatomy. Gastrointest Endosc Clin N Am 2015;25:631-56. 
182 Kim MH, Lee SK, Lee MH, et al. Endoscopic retrograde cholangiopancreatography and 
needle-knife sphincterotomy in patients with Billroth II gastrectomy: a comparative study of the 
forward-viewing endoscope and the side-viewing duodenoscope. Endoscopy 1997;29:82-5. 
183 Cicek B, Parlak E, Disibeyaz S, et al. Endoscopic retrograde cholangiopancreatography in 
patients with Billroth II gastroenterostomy. J Gastroenterol Hepatol 2007;22:1210-3. 
184 Bove V, Tringali A, Familiari P, et al. ERCP in patients with prior Billroth II gastrectomy: report 
of 30 years' experience. Endoscopy 2015;47:611-6. 
185 Bergman JJ, van Berkel AM, Bruno MJ, et al. A randomized trial of endoscopic balloon 
dilation and endoscopic sphincterotomy for removal of bile duct stones in patients with a prior 
Billroth II gastrectomy. Gastrointest Endosc 2001;53:19-26. 
186 Kim TN, Lee SH. Endoscopic Papillary Large Balloon Dilation Combined with Guidewire-
Assisted Precut Papillotomy for the Treatment of Choledocholithiasis in Patients with Billroth II 
Gastrectomy. Gut Liver 2011;5:200-3. 
187 Shah RJ, Smolkin M, Yen R, et al. A multicenter, U.S. experience of single-balloon, double-
balloon, and rotational overtube-assisted enteroscopy ERCP in patients with surgically altered 
REVISED MARKED COPY, NOV 2016.  70 
pancreaticobiliary anatomy (with video). Gastrointest Endosc 2013;77:593-600. 
188 Attam R, Leslie D, Freeman M, et al. EUS-assisted, fluoroscopically guided gastrostomy tube 
placement in patients with Roux-en-Y gastric bypass: a novel technique for access to the gastric 
remnant. Gastrointest Endosc;74:677-82. 
189 Baron TH, Song LM. Percutaneous assisted transprosthetic endoscopic therapy (PATENT): 
expanding gut access to infinity and beyond! (with video). Gastrointest Endosc 2012;76:641-4. 
190 Tyberg A, Nieto J, Salgado S, et al. Endoscopic Ultrasound (EUS)-Directed Transgastric 
Endoscopic Retrograde Cholangiopancreatography or EUS: Mid-Term Analysis of an Emerging 
Procedure. Clin Endosc 2016 doi: 10.5946/ce.2016.030. [Epub ahead of print] . 
191 Schreiner MA, Chang L, Gluck M, et al. Laparoscopy-assisted versus balloon enteroscopy-
assisted ERCP in bariatric post-Roux-en-Y gastric bypass patients. Gastrointest Endosc 2012;75:748-
56. 
 
 
16.0 Planned review date 
 
November 2021 
 
 
 
 
 
